## A. Biographical and Bibliographic Information

### IDENTIFYING DATA

1. **Name:** Andrei Horia Iagaru

## B. ACADEMIC HISTORY

### 1. Colleges and Universities Attended

| | |
|---|---|
| Oct. 1994 - Nov. 2000 | Carol Davila Medical School, Bucharest, Romania, M.D. |

### 2. Scholarships and Academic Honors (Excludes Post Degree Awards)

| | |
|---|---|
| 1994 | High School Valedictorian |
| 1995, 1997, 1999, 2000 | Carol Davila Excellence Scholarship/Dean's Honor List |
| 1996 | Education Secretary's Emeritus Scholarship |

### 3. Postdoctoral Residency and Training

| | |
|---|---|
| Jun. 2003 - Jun. 2004 | Drexel University College of Medicine, Graduate Hospital, Department of Medicine (Intern) |
| Jul. 2004 – Jun. 2005 | Keck School of Medicine of USC, LSC+USC Medical Center, Radiology Department, Division of Nuclear Medicine (Chief Resident) |
| Jul. 2005 – Jun. 2006 | Stanford School of Medicine, Stanford Hospital and Clinics, Radiology Department, Division of Nuclear Medicine (Resident) |
| Jul. 2006 – Jun. 2007 | Stanford School of Medicine, Stanford Hospital and Clinics, Radiology Department, Division of Nuclear Medicine (PET/CT Fellow) |

### 4. Certifications

| | |
|---|---|
| Oct. 2006 | American Board of Nuclear Medicine |
| Feb. 2012 | Radiography X-Ray Supervisor and Operator, ARRT |

## C. EMPLOYMENT HISTORY

### 1. Academic Appointments

| | |
|---|---|
| Jul. 2004 – Jun. 2005 | Clinical Instructor, Department of Radiology, Division of Nuclear Medicine<br>Keck School of Medicine, University of Southern California |
| Jul. 2007 – Aug. 2010 | Clinical Instructor, Department of Radiology, Division of Nuclear Medicine,<br>Stanford School of Medicine, Stanford University Medical Center |
| Sep. 2010 – May 2014 | Assistant Professor (UML), Department of Radiology, Division of Nuclear Medicine,<br>Stanford School of Medicine, Stanford University Medical Center |
| Jun. 2014 – Jan. 2019 | Associate Professor (UML), Department of Radiology, Division of Nuclear Medicine,<br>Stanford School of Medicine, Stanford University Medical Center |
| Feb. 2019 – present | Professor (UML), Department of Radiology, Division of Nuclear Medicine,<br>Stanford School of Medicine, Stanford University Medical Center |

## D. PUBLIC AND PROFESSIONAL SERVICE

### 1. Committees and Appointments

| | |
|---|---|
| 2006 - present | Ad-Hoc Reviewer: *Radiology; American Journal of Roentgenology; Journal of Nuclear Medicine; European Journal of Nuclear Medicine and Molecular Biology; Molecular Imaging and Biology; Annals of Nuclear Medicine; Nuclear Medicine Communications; Journal of Computer Assisted Tomography; Haematologica; British Journal of Cancer; Indian Journal of Cancer; American Journal of Neuroradiology* |
| 2009 - present | Editorial Board: *PLoS ONE; American Journal of Nuclear Medicine and Molecular Imaging; Clinical Nuclear Medicine; Quantitative Imaging in Medicine and Surgery; World Journal of Radiology; Journal of Nuclear Medicine; European Journal of Nuclear Medicine and Molecular Biology* |
| 2011 - 2014 | Academic Editor: *PLoS ONE* |
| 2009 – 2025 | Member: *Radiology Residency Education Committee; Clinical Radiation Safety Committee; LPCH Transformation Project Committee - Nuclear Medicine /PET-CT;* |
| 2011 - 2019 | Program Director: *Stanford Nuclear Medicine Residency Program* |
| 2012 - 2016 | Co-Chief: *Division of Nuclear Medicine and Molecular Imaging, Stanford University Medical Center* |
| 2016 – 2025 | Chief: *Division of Nuclear Medicine and Molecular Imaging, Stanford University Medical Center* |
| 2011 - 2016 | Co-Chair: *Society of Nuclear Medicine and Molecular Imaging Outreach Committee* |
| 2012 - 2016 | Co-Chair: *Society of Nuclear Medicine and Molecular Imaging Targeted Radionuclide Therapy Working Group* |
| 2013 - 2015 | Co-Chair: *Society of Nuclear Medicine and Molecular Imaging PET/MRI Task Force* |
| 2011 - 2015 | Ambassador to ASCO: *Society of Nuclear Medicine and Molecular Imaging* |
| 2013 - 2015 | Member: *Board of Directors, PET Center of Excellence (Society of Nuclear Medicine and Molecular Imaging)* |
| 2012 - 2016 | Member: *Society of Nuclear Medicine and Molecular Imaging Committee on Public Relations* |
| 2016 – 2022 | Director: *American Board of Nuclear Medicine* |
| 2013 – 2024 | Member: *National Comprehensive Cancer Network Thyroid Cancer Panel* |
| 2012 – 2025 | Member: *Scientific Review Committee, Stanford Cancer Institute* |
| 2007 - 2013 | Associate Member: *Stanford Cancer Institute* |
| 2013 - present | Member: *Stanford Cancer Institute* |
| 2013 - present | Associate Member: *Canary Center at Stanford for Early Cancer Detection* |
| 2014 – 2024 | Co-Director: *PET/MRI Research Program at Stanford University* |

| | |
|---|---|
| 2014 - present | Member: *Bio-X* |
| 2017 – 2022 | Member: *Society of Nuclear Medicine and Molecular Imaging Finance Committee* |
| 2017 - present | Member: *Society of Nuclear Medicine and Molecular Imaging Awards Committee* |
| 2017 - present | Associate Editor (Molecular Imaging): *Radiology* |
| 2018 – 2024 | Member: *ACGME Nuclear Medicine Residency Review Committee* |
| 2021 - present | Associate Editor: *European Journal of Nuclear Medicine and Molecular Biology* |
| 2023 – 2025 | Co-Chair, *SNMMI Theragnostic Leadership and Operations Group* |

## E. POST-DEGREE HONORS AND AWARDS

### 1. Honors and Awards

| | |
|---|---|
| 2007 | Travel Grant Award, ACNP Annual Meeting: "$^{18}$F FDG PET/CT Prediction of Response to Chemotherapy in Lymphoma: When is the Optimal Time for the First Re-Evaluation Scan?" (first author) |
| 2008 | Best Essay Award, ACNP Annual Meeting: "$^{131}$I-Tositumomab (Bexxar®) vs. $^{90}$Y-Ibritumomab (Zevalin®) in Refractory/Relapsed Non-Hodgkin's Lymphoma" (first author) |
| 2008 | Best Essay Award, ACNP Annual Meeting: "$^{18}$F FDG PET/CT in Head and Neck Cancers: What is the Definition of Whole-Body Scanning?" (first author) |
| 2008 | Alavi-Mandell Award, Society of Nuclear Medicine, the Journal of Nuclear Medicine (first author) |
| 2008 | Outstanding Teaching Award, Stanford Radiology Residency Program |
| 2009 | Alavi-Mandell Award, Society of Nuclear Medicine, the Journal of Nuclear Medicine (first author) |
| 2009 | Image of the Year Award, Society of Nuclear Medicine (first author) |
| 2009 | Developmental Cancer Research Award, Stanford Cancer Center |
| 2009 | Norman D. Poe Memorial Scholarship Award, Western Regional SNM Annual Meeting (first author) |
| 2010 | Best Essay Award, ACNM Annual Meeting: "Combined $^{18}$F NaF and $^{18}$F FDG PET/CT Scan for Evaluation of Malignancy: Beyond the Pilot Study" (first author) |
| 2010 | Alavi-Mandell Award, Society of Nuclear Medicine, The Journal of Nuclear Medicine (first author) |
| 2011 | Best Essay Award, ACNM Annual Meeting: "Classical Hodgkin Lymphoma in First Complete Remission: Is There a Role for $^{18}$F FDG PET/CT Surveillance?" (first author) |
| 2011 | Winner – Young Professional Tournament, 1$^{st}$ Sino-American Conference on Nuclear Medicine (first author) |
| 2011 | Radiopharmaceutical Sciences Council Travel Grant, SNM Annual Meeting (first author) |

| | |
|---|---|
| 2011 | Nuclear Oncology Council Young Investigator Award, 2nd Place, SNM Annual Meeting (first author) |
| 2011 | Norman D. Poe Memorial Scholarship Award, Western Regional SNM Annual Meeting (senior author) |
| 2013 | Winner – Young Professional Tournament, 2nd Sino-American Conference on Nuclear Medicine (senior author) |
| 2013 | Fellow, American College of Nuclear Medicine |
| 2013 | Faculty Fellowship Award, Stanford Center at Peking University |
| 2013 | Stanford Faculty Fellows Program |
| 2014 | Poster Award, ACNM Annual Meeting: "Combined $^{18}$F NaF and $^{18}$F FDG PET/CT Evaluation of Sarcoma Patients" (senior author) |
| 2014 | Norman D. Poe Memorial Scholarship Award, Western Regional SNM Annual Meeting (first author) |
| 2015 | Winner, ACNM/SNMMI Exchange Program Award: "A Prospective, Matched Comparison Study of SUV Values from non-TOF vs. TOF PET/CT Scanners" (senior author) |
| 2015 | Norman D. Poe Memorial Scholarship Award, Western Regional SNM Annual Meeting (first author) |
| 2016 | Editor's Recognition Award, Clinical Nuclear Medicine |
| 2017 | Norman D. Poe Memorial Scholarship Award, Western Regional SNM Annual Meeting (senior author) |
| 2018 | Clinician of the Year, Department of Radiology, Stanford University |
| 2020 | Sanjiv Sam Gambhir Distinguished Scientist Award, Western Regional SNM Annual Meeting |
| 2021 | Faculty of the Year, Department of Radiology, Stanford University |
| 2022 | Sanjiv Sam Gambhir Trailblazer Award, SNMMI Annual Meeting |
| 2022 | Distinguished Investigator Award, The Academy for Radiology & Biomedical Imaging Research |
| 2023 | Fellow, SNMMI |
| 2023 | Presidential Award, SNMMI |

**2. Professional Membership Associations**

| | |
|---|---|
| 2005 | Society of Nuclear Medicine and Molecular Imaging |
| 2005 | Radiological Society of North America |
| 2006 | World Molecular Imaging Society |
| 2007 | European Association of Nuclear Medicine |
| 2007 | American College of Nuclear Medicine |

## F. SCHOLARLY PUBLICATIONS

### 1. Peer Reviewed Original Research Journal Articles (Total 126)

1. **Iagaru A,** Quon A, McDougall IR, Gambhir SS. Merkel Cell Carcinoma: Is There a Role for $^{18}$F FDG PET/CT? Mol Imaging Biol. 2006 Jul-Aug;8(4):212-7.
2. **Iagaru A,** Masamed R, Singer PA, Conti PS. $^{18}$F FDG PET and PET/CT Diagnosis of Patients with Recurrent Papillary Thyroid Cancer. Mol Imaging Biol. 2006 Sep-Oct;8(5):309-14.
3. **Iagaru A**, Chawla SP, Menendez LR, Conti PS. $^{18}$F FDG PET and PET/CT for Detection of Pulmonary Metastases from Musculoskeletal Sarcomas. Nucl Med Commun. 2006 Oct;27(10):795-802.
4. **Iagaru A**, Quon A, McDougall IR, Gambhir SS. $^{18}$F FDG PET/CT Evaluation of Osseous and Soft Tissue Sarcomas. Clin Nucl Med. 2006 Dec;31(12):754-760.
5. **Iagaru A**, Quon A, Johnson D, Gambhir SS, McDougall IR. $^{18}$F FDG PET/CT in the Management of Melanoma. Mol Imaging Biol. 2007 Jan-Feb;9(1):50-7.
6. **Iagaru A**, Masamed R, Keesara S, Conti PS. Breast MRI and $^{18}$F FDG PET/CT in the Management of Breast Cancer. Ann Nucl Med. 2007 Jan;21(1):33-8.
7. **Iagaru A,** Masamed R, Singer PA, Conti PS. Detection of Occult Medullary Thyroid Cancer Recurrence with $^{18}$F FDG PET and PET/CT. Mol Imaging Biol. 2007 Mar-Apr;9(2):72-7.
8. **Iagaru A,** Kalinyak J, McDougall IR. $^{18}$F FDG PET/CT in the Management of Thyroid Cancer. Clin Nucl Med. 2007 Sep;32(9):690-5.
9. **Iagaru A**, Masamed R, Chawla S, Menendez L, Fedenko A, Conti PS. $^{18}$F FDG PET and PET/CT Evaluation of Response to Neoadjuvant Chemotherapy in Musculoskeletal and Soft-Tissue Sarcomas. Clin Nucl Med. 2008 Jan;33(1):8-13.
10. **Iagaru A**, Gambhir SS, Goris ML. $^{90}$Y-Ibritumomab (Zevalin®) Therapy in Refractory Non-Hodgkin's Lymphoma: Observations from $^{111}$In-Ibritumomab Pre-Treatment Imaging. J Nucl Med. 2008 Nov;49(11):1809-1812.
11. **Iagaru A**, Mittra ES, McDougall IR, Quon A, Gambhir SS. $^{18}$F FDG PET/CT Evaluation of Patients with Ovarian Carcinoma. Nucl Med Commun. 2008 Dec;29(12):1046-51.
12. **Iagaru A**, Wang, Y, Mari C, Quon A, Goris ML, Horning S, Gambhir SS. $^{18}$F FDG PET/CT Evaluation of Response to Therapy in Lymphoma: When is the Optimal Time for the First Re-evaluation Scan? Hell J Nucl Med. 2008 Sep-Dec;11(3):153-6.
13. **Iagaru A**, Mittra ES, Yaghoubi S, Dick DW, Quon A, Goris ML, Gambhir SS. A Novel Strategy for a Cocktail $^{18}$F Fluoride and $^{18}$F FDG PET/CT Scan for Evaluation of Malignancy: Results of the Pilot Phase Study. J Nucl Med. 2009 Apr;50(4):501-5.
14. **Iagaru A**, Kundu R, Jadvar H, Nagle D. Evaluation by $^{18}$F FDG PET of patients with anal squamous cell carcinoma. Hell J Nucl Med. 2009 Jan-Apr;12(1):26-8.
15. Mittra ES, El-Maghraby T, Rodriguez CA, Quon A, McDougall IR, Gambhir SS, **Iagaru A**. Efficacy of $^{18}$F-FDG PET/CT in the Evaluation of Patients with Recurrent Cervical Carcinoma. Eur J Nucl Med Mol Imaging. 2009 Dec;36(12):1952-9.
16. **Iagaru A**, Mittra ES, Ganjoo K, Knox SJ, Goris ML. $^{131}$I-Tositumomab (Bexxar®) vs. $^{90}$Y-Ibritumomab (Zevalin®) Therapy of Refractory/Relapsed Non-Hodgkin Lymphoma. Mol Imaging Biol. 2010 Apr;12(2):198-203.
17. **Iagaru A**, Mittra ES, Gambhir SS. $^{18}$F FDG PET/CT in Cancers of the Head and Neck: What is the Definition of Whole-Body Scanning? Mol Imaging Biol. 2011 Apr;13(2):362-7.
18. Mittra ES, Goris ML, **Iagaru A,** Kardan A, Burton L, Berganos R, Chang E, Liu S, Shen B, Chin FT, Chen X, Gambhir SS. Pilot Pharmacokinetic and Dosimetric Studies of $^{18}$F FPPRGD$_2$: A PET Radiopharmaceutical Agent for Imaging $\alpha_v\beta_3$ Integrin Levels. Radiology. 2011 Jul;260(1):182-91.
19. Murphy JD, Chisholm KM, Daly ME, Wiegner EA, Truong D, **Iagaru A**, Maxim PG, Loo BW Jr, Graves EE, Kaplan MJ, Kong C, Le QT. Correlation between metabolic tumor volume and pathologic tumor volume in squamous cell carcinoma of the oral cavity. Radiother Oncol. 2011 Dec;101(3):356-61.

20. Sze DY, **Iagaru A**, Gambhir S, de Haan H, Reid T. Response to intraarterial oncolytic virotherapy with the Herpes virus NV-1020 evaluated by $^{18}$F fluorodeoxyglucose positron emission tomography and computed tomography. Hum Gene Ther. 2012 Jan;23(1):91-7.

21. Lin FI, Rao J, Mittra ES, Nallapareddy K, Chengapa A, Dick DW, Gambhir SS, **Iagaru A**. Prospective Comparison of Combined $^{18}$F FDG and $^{18}$F NaF PET/CT vs. $^{18}$F FDG PET/CT Imaging for Detection of Malignancy. Eur J Nucl Med Mol Imaging. 2012 Feb;39(2):262-70.

22. **Iagaru A,** Mittra ES, Dick DW, Gambhir SS. Prospective Evaluation of $^{99m}$Tc MDP Scintigraphy, $^{18}$F NaF PET/CT and $^{18}$F FDG PET/CT for Detection of Skeletal Metastases. Mol Imaging Biol. 2012 Apr;14(2):252-9.

23. Tang C, Murphy JD, Khong B, La TH, Kong C, Fischbein NJ, Colevas AD, **Iagaru A**, Graves EE, Loo BW Jr, Le QT. Validation that Metabolic Tumor Volume Predicts Outcome in Head-and-Neck Cancer. Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1514-20.

24. Chu KP, Murphy JD, La TH, Krakow TE, **Iagaru A**, Graves EE, Hsu A, Maxim PG, Loo B, Chang DT, Le QT. Prognostic Value of Metabolic Tumor Volume and Velocity in Predicting Head-and-Neck Cancer Outcomes. Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1521-7.

25. Natarajan A, Gowrishankar G, Nielsen CH, Wang S, **Iagaru A**, Goris ML, Gambhir SS. Positron Emission Tomography of (64)Cu-DOTA-Rituximab in a Transgenic Mouse Model Expressing Human CD20 for Clinical Translation to Image NHL. Mol Imaging Biol. 2012 Oct;14(5):608-16.

26. Quon A, Dodd R, **Iagaru A**, de Abreu MR, Hennemann S, Neto JM, Sprinz C. Initial investigation of $^{18}$F-NaF PET/CT for identification of vertebral sites amenable to surgical revision after spinal fusion surgery. Eur J Nucl Med Mol Imaging. Eur J Nucl Med Mol Imaging. 2012 Nov;39(11):1737-44.

27. **Iagaru A**, Mittra ES, Dick DW, Mosci C, Sathekge M, Prakash V, Iyer V, Lapa P, Isidoro J, de Lima JM, Gambhir SS. Combined $^{18}$F FDG and $^{18}$F NaF PET/CT Scan for Evaluation of Malignancy: Results of an International Multi-Center Trial. J Nucl Med. 2013 Feb;54(2):176-83.

28. **Iagaru A**, Young PM, Mittra ES, Dick DW, Herfkens R, Gambhir SS. Pilot Prospective Evaluation of $^{99m}$Tc-MDP Scintigraphy, $^{18}$F NaF PET/CT, $^{18}$F FDG PET/CT and Whole-Body MRI for Detection of Skeletal Metastases. Clin Nucl Med. 2013 Jul;38(7):e290-6.

29. Nair VS, Keu KV, Luttgen MS, Kolatkar A, Vasanawala M, Kuschner W, Bethel K, **Iagaru A**, Hoh C, Shrager JB, Loo BW Jr, Bazhenova L, Nieva J, Gambhir SS, Kuhn P. An Observational Study of Circulating Tumor Cells and $^{18}$F-FDG PET Uptake in Patients with Treatment-Naive Non-Small Cell Lung Cancer. PLoS One. 2013 Jul 5;8(7):e67733.

30. Lam MG, Louie JD, **Iagaru A**, Goris ML, Sze DY. Safety of Repeated Yttrium-90 Radioembolization. Cardiovasc Intervent Radiol. Cardiovasc Intervent Radiol. 2013 Oct;36(5):1320-8.

31. **Iagaru A**, Mosci C, Dick DW, Sathekge M, Lapa P, de Lima JM, Gambhir SS. Combined $^{18}$F-fluoride and $^{18}$F-FDG PET/CT: a response based on actual data from prospective studies. Eur J Nucl Med Mol Imaging. 2013 Dec;40(12):1922-4.

32. Lam MG, Banerjee S, Louie JD, Abdelmaksoud MH, **Iagaru A**, Ennen RE, Sze DY. Root Cause Analysis of Gastroduodenal Ulceration After Yttrium-90 Radioembolization. Cardiovasc Intervent Radiol. 2013 Dec;36(6):1536-47.

33. Lam MG, Goris ML, **Iagaru A**, Mittra ES, Louie JD, Sze DY. Prognostic Utility of 90Y Radioembolization Dosimetry Based on Fusion 99mTc-Macroaggregated Albumin-99mTc-Sulfur Colloid SPECT. J Nucl Med. 2013 Dec;54(12):2055-61.

34. Takehana C, Twist C, Mosci C, Mittra ES, Quon A, Gambhir SS, **Iagaru A**. $^{18}$F FDG PET/CT in the Management of Patients with Post-Transplant Lymphoproliferative Disorder. Nucl Med Commun. 2014 Mar;35(3):276-81.

35. **Iagaru A**, Mosci C, Shen B, Chin FT, Mittra ES, Telli ML, Gambhir SS. $^{18}$F FPPRGD$_2$ PET/CT: Pilot Phase Evaluation of Breast Cancer Patients. Radiology. 2014 Nov;273(2):549-59.

36. **Iagaru A**, Mittra E, Minamimoto R, Jamali M, Levin C, Quon A, Gold G, Herfkens R, Vasanawala S, Gambhir SS, Zaharchuk G. Simultaneous whole-body time-of-flight $^{18}$F-FDG PET/MRI: a pilot study comparing $SUV_{max}$ with PET/CT and assessment of MR image quality. Clin Nucl Med. 2015 Jan;40(1):1-8.

37. Sampath S, Sampath S, Mosci C, Lutz A, Willmann JK, Mittra ES, Gambhir SS, **Iagaru A**. Detection of Osseous Metastases by Combined $^{18}$F NaF/$^{18}$F FDG PET/CT versus CT Alone. Clin Nucl Med. 2015 Mar;40(3):e173-7.

38. Natarajan A, Arksey N, **Iagaru A**, Chin FT, Gambhir SS. Validation of $^{64}$Cu-DOTA-Rituximab Injection Preparation Under Good Manufacturing Practices: A PET Tracer for Imaging of B-Cell Non-Hodgkin Lymphoma. Mol Imaging. 2015 Mar 1;14(0):1-11.

39. Sabbah N, Jackson T, Mosci C, Jamali M, Minamimoto R, Quon A, Mittra ES, **Iagaru A**. $^{18}$F-Sodium Fluoride PET/CT in Oncology: An Atlas of SUVs. Clin Nucl Med. 2015 Apr;40(4):e228-31.

40. Smits ML, Elschot M, Sze DY, Kao YH, Nijsen JF, **Iagaru A**, de Jong HW, van den Bosch MA, Lam MG. Radioembolization Dosimetry: The Road Ahead. Cardiovasc Intervent Radiol. 2015 Apr;38(2):261-9.

41. Minamimoto R, Mosci C, Jamali M, Barkhodari A, Habte F, Jackson T, Mittra E, Gambhir SS, **Iagaru A**. Semiquantitative Analysis of the Biodistribution of the Combined $^{18}$F NaF and $^{18}$F FDG Administration for PET/CT Imaging. J Nucl Med. 2015 May;56(5):688-94.

42. Loo BW Jr, Soltys SG, Wang L, Lo A, Fahimian BP, **Iagaru A**, Norton L, Shan X, Gardner E, Fogarty T, Maguire P, Al-Ahmad A, Zei P. Stereotactic ablative radiotherapy for the treatment of refractory cardiac ventricular arrhythmia. Circ Arrhythm Electrophysiol. 2015 Jun;8(3):748-50.

43. Lam MG, Banerjee A, Goris ML, **Iagaru A**, Mittra ES, Louie JD, Sze DY. Fusion dual-tracer SPECT-based hepatic dosimetry predicts outcome after radioembolization for a wide range of tumour cell types. Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1192-201.

44. Jackson T, Mosci C, von Eyben R, Mittra ES, Ganjoo K, Biswal S, Gambhir SS, **Iagaru A**. Combined $^{18}$F NaF and $^{18}$F FDG PET/CT in the Evaluation of Sarcoma Patients. Clin Nucl Med. 2015 Sep;40(9):720-4.

45. Minamimoto R, Jamali M, Barkhodari A, Mosci C, Mittra E, Shen B, Chin FT, Gambhir SS, **Iagaru A**. Biodistribution of the $^{18}$F FPPRGD$_2$ PET Radiopharmaceutical in Cancer Patients: An Atlas of SUV Measurements. Eur J Nucl Med Mol Imaging. 2015 Nov;42(12):1850-8.

46. **Iagaru A**, Mosci C, Mittra E, Zaharchuk G, Fischbein N, Harsh G, Li G, Nagpal S, Recht L, Gambhir SS. Glioblastoma Multiforme Recurrence: An Exploratory Study of $^{18}$F FPPRGD$_2$ PET/CT. Radiology. 2015 Nov;277(2):497-506.

47. Minamimoto R, Loening A, Jamali M, Barkhodari A, Mosci C, Jackson T, Obara P, Taviani V, Gambhir SS, Vasanawala S, **Iagaru A**. Prospective Comparison of $^{99m}$Tc-MDP Scintigraphy, Combined $^{18}$F-NaF and $^{18}$F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer. J Nucl Med. 2015 Dec;56(12):1862-8.

48. Minamimoto R, Mitsumoto T, Miyata Y, Sunaoka F, Morooka M, Okasaki M, **Iagaru A**, Kubota K. Evaluation of a new motion correction algorithm in PET/CT: combining the entire acquired PET data to create a single three-dimensional motion-corrected PET/CT image. Nucl Med Commun. 2016 Feb;37(2):162-70.

49. Mittra ES, Koglin N, Mosci C, Kumar M, Hoehne A, Keu KV, **Iagaru A**, Mueller A, Berndt M, Bullich S, Friebe M, Schmitt-Willich H, Gekeler V, Fels LM, Bacher-Stier C, Moon DH, Chin FT, Stephens AW, Dinkelborg LM, Gambhir SS. Pilot Preclinical and Clinical Evaluation of (4S)-4-(3-[18F]Fluoropropyl)-L-Glutamate (18F-FSPG) for PET/CT Imaging of Intracranial Malignancies. PLoS One. 2016 Feb 18;11(2):e0148628.

50. Minamimoto R, Hancock S, Schneider B, Chin FT, Jamali M, Loening A, Vasanawala S, Gambhir SS, **Iagaru A**. Pilot Comparison of $^{68}$Ga-RM2 PET and $^{68}$Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer. J Nucl Med. 2016 Apr;57(4):557-62.

51. Minamimoto R, Karam A, Jamali M, Barkhodari A, Gambhir SS, Dorigo O, **Iagaru A**. Pilot prospective evaluation of $^{18}$F-FPPRGD$_2$ PET/CT in patients with cervical and ovarian cancer. Eur J Nucl Med Mol Imaging. 2016 Jun;43(6):1047-55.

52. Moradi F, Jamali M, Barkhodari A, Schneider B, Chin F, Quon A, Mittra ES, **Iagaru A**. Spectrum of $^{68}$Ga-DOTA TATE Uptake in Patients with Neuroendocrine Tumors. 2016 Jun;41(6):e281-7.

53. Thompson HM, Minamimoto R, Jamali M, Barkhodari A, von Eyben R, **Iagaru A**. A Prospective, Matched Comparison Study of SUV Measurements From Time-of-Flight Versus Non-Time-of-Flight PET/CT Scanners. Clin Nucl Med. 2016 Jul;41(7):e323-6.

54. Guo HH, Moradi F, **Iagaru A.** Clinical Significance of Extra-skeletal CT Findings on $^{18}$F-NaF PET/CT Performed for Osseous Metastatic Disease Evaluation. Nucl Med Commun. 2016 Sep;37(9):975-82.

55. Minamimoto R, Levin C, Jamali M, Holley D, Barkhodari A, Zaharchuk G, **Iagaru A**. Improvements in PET Image Quality in Time of Flight (TOF) Simultaneous PET/MRI. Mol Imaging Biol. 2016 Oct;18(5):776-81.

56. Minamimoto R, **Iagaru A**, Jamali M, Holley D, Barkhodari A, Vasanawala S, Zaharchuk G. Conspicuity of Malignant Lesions on PET/CT and Simultaneous Time-Of-Flight PET/MRI. PLoS One. 2017 Jan 19;12(1):e0167262.

57. Lapa P, Marques M, Costa G, **Iagaru A**, Pedroso de Lima J. Assessment of skeletal tumour burden on 18F-NaF PET/CT using a new quantitative method. Nucl Med Commun. 2017 Apr;38(4):325-332.

58. Baratto L, Park S, Hatami N, Davidzon G, Srinivas SS, Gambhir SS, **Iagaru A**. SiPM PET/CT vs. Standard PET/CT: A Pilot Study Comparing Semi-Quantitative Measurements in Normal Tissues and Lesions. PLoS One. Jun 5;12(6):e0178936.

59. Ter Voert EE, Veit-Haibach P, Ahn S, Wiesinger F, Khalighi MM, Levin CS, **Iagaru A**, Zaharchuk G, Huellner M, Delso G. Clinical evaluation of TOF versus non-TOF on PET artifacts in simultaneous PET/MR: a dual centre experience. Eur J Nucl Med Mol Imaging. 2017 Jul;44(7):1223-1233.

60. Hanneman K, Kadoch M, Guo HH, Jamali M, Quon A, **Iagaru A**, Herfkens R. Initial Experience With Simultaneous $^{18}$F-FDG PET/MRI in the Evaluation of Cardiac Sarcoidosis and Myocarditis. Clin Nucl Med. 2017 Jul;42(7):e328-e334.

61. Minamimoto R, Xu G, Jamali M, Holley D, Barkhodari A, Zaharchuk G, **Iagaru A**. Semi-quantitative assessment of $^{18}$F FDG uptake in the normal skeleton: comparison between PET/CT and time of flight simultaneous PET/MRI. AJR Am J Roentgenol. 2017 Nov;209(5):1136-1142.

62. Koerber SA, Utzinger MT, Kratochwil C, Kesch C, Haefner MF, Katayama S, Mier W, **Iagaru A**, Herfarth K, Haberkorn U, Debus J, Giesel FL. $^{68}$Ga-PSMA-11 PET/CT in Newly Diagnosed Carcinoma of the Prostate: Correlation of Intraprostatic PSMA Uptake with Several Clinical Parameters. J Nucl Med. 2017 Dec;58(12):1943-1948.

63. Baratto L, Davidzon GA, Moghbel M, Hatami N, **Iagaru A**, Mittra ES. Comparison Between Different PET and CT-Based Imaging Interpretation Criteria at Interim Imaging in Patients With Diffuse Large B-Cell Lymphoma. Clin Nucl Med. 2018 Jan;43(1):1-8.

64. Sartor O, Vogelzang NJ, Sweeney C, Fernandez DC, Almeida F, **Iagaru A**, Brown A Jr., Smith MR, Agrawal M, Dicker AP, Garcia JA, Lutzky J, Wong YN, Petrenciuc O, Gratt J, Shore ND, Morris MJ; U.S. Expanded Access Program Investigators. Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program. Oncologist. 2018 Feb;23(2):193-202.

65. Obara P, Loening A, Taviani V, **Iagaru A**, Hargreaves BA, Vasanawala S. Relative value of three whole-body MR approaches for PET-MR, including gadofosveset-enhanced MR, in comparison to PET-CT. Clin Imaging. 2018 Mar - Apr;48:62-68.

66. Orthey P, Yu D, Van Natta ML, Ramsey FV, Diaz JR, Bennett PA, **Iagaru A**, Fragomeni RS, McCallum RW, Sarosiek I, Hasler WL, Farrugia G, Grover M, Koch KL, Nguyen L, Snape WJ, Abell TL, Pasricha PJ, Tonascia J, Hamilton F, Parkman HP, Maurer AH; NIH Gastroparesis Consortium. Intragastric Meal Distribution During Gastric Emptying Scintigraphy for Assessment of Fundic Accommodation: Correlation with Symptoms of Gastroparesis. J Nucl Med. 2018 Apr;59(4):691-697.

67. Sonni I, Park S, Baratto L, Hatami N, Davidzon G, Srinivas S, **Iagaru A**. Initial experience with a SiPM-based PET/CT scanner: influence of acquisition time on image quality. EJNMMI Phys. 2018 Apr 18;5(1):9.

68. Lantos J, Mittra E, Levin CS, **Iagaru A**. Standard OSEM vs. Regularized PET Image Reconstruction: Qualitative and Quantitative Comparison Using Phantom Data and Various Clinical Radiopharmaceuticals. Am J Nucl Med Mol Imaging. 2018 Apr 25;8(2):110-118.

69. Minamimoto R, Sonni I, Hancock S, Vasanawala S, Loening A, Gambhir SS, **Iagaru A**. Prospective Evaluation of $^{68}$Ga-RM2 PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer and Negative Conventional Imaging. J Nucl Med. 2018 May;59(5):803-808.

70. Kogan F, Fan AP, Monu U, **Iagaru A**, Hargreaves BA, Gold GE. Quantitative imaging of bone-cartilage interactions in ACL-injured patients with PET-MRI. Osteoarthritis Cartilage. 2018 Jun;26(6):790-796.

71. Baratto L, Park SY, Hatami N, Gulaka P, Vasanawala S, Yohannan TK, Herfkens R, Witteles R, **Iagaru A**. $^{18}$F-florbetaben whole-body PET/MRI for evaluation of systemic amyloid deposition. EJNMMI Res. 2018 Jul 24;8(1):66.

72. Park S, Zacharias C, Harrison C, Fan R, Kunder C, Ghanouni P, Sonn P, **Iagaru A**. $^{68}$Ga-PSMA-11 PET/MRI in Patients with Newly Diagnosed Intermediate or High-Risk Prostate Cancer. Radiology. 2018 Aug;288(2):495-505.

73. Wangerin KA, Baratto L, Khalighi MM, Hope TA, Gulaka PK, Deller TW, **Iagaru A**. Clinical evaluation of $^{68}$Ga-PSMA-11 and $^{68}$Ga-RM2 PET images reconstructed with an improved scatter correction algorithm. AJR Am J Roentgenol. 2018 Sep;211(3):655-660.

74. Li D, Zhang J, Ji N, Zhao X, Zheng K, Qiao Z, Li F, Lang L, **Iagaru A**, Niu G, Zhu Z, Chen X. Combined $^{68}$Ga-NOTA-PRGD$_2$ and $^{18}$F-FDG PET/CT Can Discriminate Uncommon Meningioma Mimicking High-Grade Glioma. Clin Nucl Med. 2018 Sep;43(9):648-654.

75. Hong S, Mosci C, Akatsu H, Basina M, Dosiou C, McDougall IR, **Iagaru A**. Diagnostic $^{123}$I Whole Body Scan Prior to Ablation of Thyroid Remnant in Patients with Papillary Thyroid Cancer: Implications for Clinical Management. Clin Nucl Med. 2018 Oct;43(10):705-709.

76. Ning N, Guo HH, **Iagaru A**, Mittra E, Fowler M, Witteles R. Serial Cardiac FDG-PET for the Diagnosis and Therapeutic Guidance of Patients with Cardiac Sarcoidosis. J Card Fail. 2019 Apr;25(4):307-311.

77. Toriihara A, Duan H, Thompson HM, Park S, Hatami N, Baratto L, Fan AC, **Iagaru A.** $^{18}$F-FPPRGD$_2$ PET/CT in patients with metastatic renal cell cancer. Eur J Nucl Med Mol Imaging. 2019 Jul;46(7):1518-1523.

78. Twist CJ, Hiniker SM, Gratzinger D, Gutkin PM, Merriott DJ, **Iagaru A**, Link MP, Donaldson SS. Treatment and outcomes in classic Hodgkin lymphoma post-transplant lymphoproliferative disorder in children. Pediatr Blood Cancer. 2019 Aug;66(8):e27803.

79. Toriihara A, Baratto L, Nobashi T, Park S, Hatami N, Davidzon G, Kunz P, **Iagaru A**. Prognostic value of volumetric parameters calculated from $^{68}$Ga-DOTATATE PET/CT in patients with well-differentiated neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2019 Oct;46(11):2244-2251.

80. Baratto L, Duan H, Laudicella R, Toriihara A, Hatami N, Ferri V, **Iagaru A**. Physiological $^{68}$Ga-RM2 Uptake in Patients with Biochemically Recurrent Prostate Cancer: An Atlas of Semi-Quantitative Measurements. Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):115-122.

81. Bachawal SV, Park JM, Valluru KS, Loft MD, Felt SA, Vilches-Moure JG, Saenz YF, Daniel B, **Iagaru A**, Sonn G, Cheng Z, Spielman DM, Willmann JK. Multimodality Hyperpolarized C-13 MRS/PET/Multiparametric MR Imaging for Detection and Image-Guided Biopsy of Prostate Cancer: First Experience in a Canine Prostate Cancer Model. Mol Imaging Biol. 2019 Oct;21(5):861-870.

82. Christian PE, Williams SP, Burrel L, Castaneda P, Albiani J, Sandella N, **Iagaru A**, Hoffman JM, de Crespigny A, Bohorquez SS. Optimization of 89Zr PET Imaging for Improved Multisite Quantification and Lesion Detection Using an Anthropomorphic Phantom. J Nucl Med Technol. 2020 Mar;48(1):54-57.

83. Kimura RH, Wang L, Shen B, Huo L, Tummers W, Filipp FV, Guo HH, Haywood T, Abou-Elkacem L, Baratto L, Habte F, Devulapally R, Witney TH, Cheng Y, Tikole S, Chakraborti S, Nix J, Bonagura CA, Hatami N, Mooney JJ, Desai T, Turner S, Gaster RS, Otte A, Visser BC, Poultsides GA, Norton J, Park W, Stolowitz M, Lau K, Yang E, Natarajan A, Ilovich O, Srinivas S, Srinivasan A, Paulmurugan R, Willmann J, Chin FT, Cheng Z, **Iagaru A**, Li F, Gambhir SS. Evaluation of integrin $\alpha_v\beta_6$ cystine knot PET tracers to detect cancer and idiopathic pulmonary fibrosis. Nat Commun. 2019 Oct 14;10(1):4673.

84. Park SY, Barrato L, Hatami N, Davidzon G, Gambhir SS, **Iagaru A.** Initial experience with a PET/computed tomography system using silicon photomultiplier detectors. Nucl Med Commun. 2019 Nov;40(11):1174-1178.

85. Beinat C, Patel CB, Haywood T, Shen B, Naya L, Gandhi H, Holley D, Khalighi M, **Iagaru A**, Davidzon G, Gambhir SS. Human biodistribution and radiation dosimetry of [$^{18}$F]DASA-23, a PET probe targeting pyruvate kinase M2. Eur J Nucl Med Mol Imaging. 2020 Jan 15. doi: 10.1007/s00259-020-04687-0. Online ahead of print.

86. Sonni I, Minamimoto R, Loening AM, Taviani V, Hatami N, Gambhir SS, Vasanawala SS, **Iagaru A**. Imaging Patients with Breast and Prostate Cancers Using Combined $^{18}$F NaF/$^{18}$F FDG and TOF simultaneous PET/ MRI. Mol Imaging Biol. 2020 Apr;22(2):397-406

87. Nobashi T, Zacharias C, Ellis JK, Ferri V, Koran ME, Franc BL, **Iagaru A**, Davidzon GA. Performance Comparison of Individual and Ensemble CNN Models for the Classification of Brain $^{18}$F-FDG-PET Scans. J Digit Imaging. 2020 Apr;33(2):447-455.

88. Song H, Harrison C, Duan H, Guja K, Hatami N, Franc BL, Moradi F, Aparici CM, Davidzon GA, **Iagaru A.** Prospective Evaluation of $^{18}$F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer in an Academic Center: A Focus on Disease Localization and Changes in Management. J Nucl Med. 2020 Apr;61(4):546-551.

89. Toriihara A, Nobashi T, Baratto L, Duan H, Moradi F, Park S, Hatami N, Aparici CM, Davidzon G, **Iagaru A.** Comparison of 3 Interpretation Criteria for $^{68}$Ga-PSMA11 PET Based on Inter- And Intrareader Agreement. J Nucl Med. 2020 Apr;61(4):533-539.

90. Baratto L, Duan H, Ferri V, Khalighi M, **Iagaru A**. The effect of various β values on image quality and semi-quantitative measurements in $^{68}$Ga-RM2 and $^{68}$Ga-PSMA-11 PET/MRI images reconstructed with a block sequential regularized expectation maximization algorithm. Clin Nucl Med. 2020 2020 Jul;45(7):506-513.

91. Nakamoto R, Zaba LC, Rosenberg J, Reddy SA, Nobashi TW, Davidzon G, Aparici CM, Nguyen J, Moradi F, **Iagaru A**, Franc BL. Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy. Eur J Nucl Med Mol Imaging. 2020 Nov;47(12):2787-2795.

92. Lee JJ, Yang H, Franc BL, **Iagaru A**, Davidzon GA. Deep learning detection of prostate cancer recurrence with 18F-FACBC (fluciclovine, Axumin®) positron emission tomography. Eur J Nucl Med Mol Imaging. 2020 Dec;47(13):2992-2997.

93. Natarajan A, Srinivas SM, Azevedo C, Greene L, Bauchet AL, Jouannot E, Lacoste-Bourgeacq AS, Guizon I, Cohen P, Naneix AL, Ilovich O, Cisneros J, Rupanarayan K, Chin FT, **Iagaru A**, Dirbas FM, Karam A, Gambhir SS. Two Patient Studies of a Companion Diagnostic Immuno-Positron Emission Tomography (PET) Tracer for Measuring Human CA6 Expression in Cancer for Antibody Drug Conjugate (ADC) Therapy. Mol Imaging. 2020 Jan-Dec;19:1536012120939398.

94. Jarr KU, Nakamoto R, Doan BH, Kojima Y, Weissman IL, Advani RH, **Iagaru A**, Leeper NJ. Effect of CD47 Blockade on Vascular Inflammation. N Engl J Med. 2021 Jan 28;384(4):382-383.

95. Nakamoto R, C Zaba L, Rosenberg J, Arani Reddy S, W Nobashi T, Ferri V, Davidzon G, Mari Aparici C, Nguyen J, Moradi F, **Iagaru A**, Franc BL. Imaging Characteristics and Diagnostic Performance of 2-deoxy-2-[18F]fluoro-D-Glucose PET/CT for Melanoma Patients Who Demonstrate Hyperprogressive Disease When Treated with Immunotherapy. Mol Imaging Biol. 2021 Feb;23(1):139-147.

96. Krishnan G, van den Berg NS, Nishio N, Juniper G, Pei J, Zhou Q, Lu G, Lee YJ, Ramos K, **Iagaru A**, Baik FM, Colevas AD, Martin BA, Rosenthal EL. Metastatic and sentinel lymph node mapping using intravenously delivered Panitumumab-IRDye800CW. Theranostics. 2021 May 24;11(15):7188-7198.

97. Baratto L, Toriihara1 A, Hatami N, Duan H, Mari Aparici C, Davidzon G, Levin CS, **Iagaru A**. Results of a Prospective Randomized Trial to Compare $^{68}$Ga-DOTA-TATE with SiPM-based PET/CT vs. Conventional PET/CT in Patients with Neuroendocrine Tumors. Diagnostics (Basel). 2021 May 30;11(6):992).

98. Morris MJ, Rowe SP, Gorin MA, Saperstein L, Pouliot F, Josephson D, Wong JYC, Pantel AR, Cho SY, Gage KL, Piert M, **Iagaru A**, Pollard JH, Wong V, Jensen J, Lin T, Stambler N, Carroll PR, Siegel BA; CONDOR Study Group. Diagnostic Performance of $^{18}$F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study. Clin Cancer Res. 2021 Jul 1;27(13):3674-3682.

99. Duan H. Khalaf MH, Ferri V, Baratto L, Srinivas SM, Sze DY, **Iagaru A**. High quality imaging and dosimetry for yttrium-90 ($^{90}$Y) liver radioembolization using a SiPM-based PET/CT scanner. Eur J Nucl Med Mol Imaging. 2021 Jul;48(8):2426-2436.

100. Nakamoto R, Harrison C, Song H, Guja KE, Hatami N, Nguyen J, Moradi F, Franc BL, Mari Aparici C, Davidzon G, **Iagaru A**. Diagnostic Performance of $^{18}$F-Fluciclovine PET/CT in Biochemically Recurrent Prostate Cancer: An Academic Center Experience Post FDA-Approval. Mol Imaging Biol. 2021 Aug;23(4):614-623.

101. Nakamoto R, Zaba LC, Liang T, Reddy SA, Davidzon G, Aparici CM, Nguyen J, Moradi F, **Iagaru A**, Franc BL. Prognostic value of bone marrow metabolism on pretreatment $^{18}$F-FDG PET/CT in patients with metastatic melanoma treated with anti-PD-1 therapy. J Nucl Med. 2021 Oct;62(10):1380-1383.

102. Baratto L, Song H, Duan H, Hatami N, Bagshaw H, Buyyounouski M, Hancock S, Shah S, Srinivas S, Swift P, Moradi F, Davidzon G, **Iagaru A**. PSMA- and GRPR-targeted PET: Preliminary Results in Patients with Biochemically Recurrent Prostate Cancer. J Nucl Med. 2021 Nov;62(11):1545-1549.

103. Beinat C, Patel CB, Haywood T, Murty S, Naya L, Castillo JB, Reyes ST, Phillips M, Buccino P, Shen B, Park JH, Koran MEI, Alam IS, James ML, Holley D, Halbert K, Gandhi H, He JQ, Granucci M, Johnson E, Liu DD, Uchida N, Sinha R, Chu P, Born DE, Warnock GI, Weissman I, Hayden-Gephart M, Khalighi M, Massoud TF, **Iagaru A**, Davidzon G, Thomas R, Nagpal S, Recht LD, Gambhir SS. A Clinical PET Imaging Tracer ([$^{18}$F]DASA-23) to Monitor Pyruvate Kinase M2-Induced Glycolytic Reprogramming in Glioblastoma. Clin Cancer Res. 2021 Dec 1;27(23):6467-6478.

104. Duan H, Baratto L, Hatami N, Liang T, Mari Aparici C, Davidzon GA, **Iagaru A**. $^{68}$Ga-PSMA11 PET/CT for biochemically recurrent prostate cancer: Influence of dual-time and PMT- vs SiPM-based detectors. Transl Oncol. 2022 Jan;15(1):101293.

105. Duan H, Baratto L, Hatami N, Liang T, Levin CS, Khalighi MM, **Iagaru A**. Reduced Acquisition Time Per Bed Position for PET/MRI Using $^{68}$Ga-RM2 or $^{68}$Ga-PSMA11 in Patients with Prostate Cancer: A Retrospective Analysis. AJR Am J Roentgenol. 2022 Feb;218(2):333-340.

106. Minamimoto R, Baratto L, **Iagaru A**. Association Between Time Since Administration of Pegylated G-CSF (Pegfilgrastim) and Bone Marrow Uptake on FDG PET/CT: Determination of a Minimum Interval. AJR Am J Roentgenol. 2022 Feb;218(2):351-358.

107. Duan H, Ferri V, Fisher GA, Shaheen S, Davidzon GA, **Iagaru A**, Mari Aparici C. Evaluation of Liver and Renal Toxicity in Peptide Receptor Radionuclide Therapy for Somatostatin Receptor Expressing Tumors: A 2-Year Follow-Up. Oncologist. 2022 Jun 8;27(6):447-452.

108. Lee YJ, van den Berg NS, Duan H, Azevedo EC, Ferri V, Hom M, Raymundo RC, Valencia A, Castillo J, Shen B, Zhou Q, Freeman L, Koran ME, Kaplan MJ, Colevas AD, Baik FM, Chin FT, Martin BA, **Iagaru A**, Rosenthal EL. $^{89}$Zr-panitumumab Combined With 18F-FDG PET Improves Detection and Staging of Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2022 Oct 14;28(20):4425-4434.

109. Moradi F, Duan H, Song H, Davidzon GA, Chung BI, Thong AEC, Loening AM, Ghanouni P, Sonn G, **Iagaru A**. $^{68}$Ga-PSMA11 PET/MRI in patients with newly diagnosed intermediate or high-risk prostate adenocarcinoma: PET findings correlate with outcomes after definitive treatment. J Nucl Med. 2022 Dec;63(12):1822-1828.

110. Duan H, Baratto L, Fan RE, Soerensen SJC, Liang T, Chung BI, Thong AEC, Gill H, Kunder C, Stoyanova T, Rusu M, Loening AM, Ghanouni P, Davidzon GA, Moradi F, Sonn GA, **Iagaru A**. Correlation of $^{68}$Ga-RM2 PET with Post-Surgery Histopathology Findings in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer. J Nucl Med. 2022 Dec;63(12):1829-1835.

111. Nakamoto R, Ferri V, Duan H, Hatami N, Goel M, Rosenberg J, Kimura R, Wardak M, Haywood T, Kellow R, Shen B, Park W, **Iagaru A**, Gambhir SS. Pilot-phase PET/CT study targeting integrin $\alpha_v\beta_6$ in pancreatic cancer patients using the cystine-knot peptide-based $^{18}$F-FP-R01-MG-F2. Eur J Nucl Med Mol Imaging. 2022 Dec;50(1):184-193.

112. Hu Z, Bieniosek M, Ferri V, **Iagaru A**, Kovalchuk N, Han B, Xing L, Vitzthum L, Olcott P, Narayanan M, Laurence T, Ren Y, Oderinde OM, Shirvani SM, Chang D, Surucu M. Image-mode performance characterization of a positron emission tomography subsystem designed for Biology-guided radiotherapy (BgRT) Br J Radiol. 2023 Jan 1;96(1141):20220387.

113. Duan H, Ghanouni P, Daniel B, Rosenberg J, Davidzon GA, Mari Aparici C, Kunder C, Sonn G, **Iagaru A.** A Pilot Study of $^{68}$Ga-PSMA11 and $^{68}$Ga-RM2 PET/MRI for Evaluation of Prostate Cancer Response to High Intensity Focused Ultrasound (HIFU) Therapy. J Nucl Med. 2023 Apr;64(4):592-597.

114. Duan H, Ghanouni P, Daniel B, Rosenberg J, Thong A, Kunder C, Mari Aparici C, Davidzon GA, Moradi F, Sonn GA, **Iagaru A**. A Pilot Study of $^{68}$Ga-PSMA11 and $^{68}$Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer. J Nucl Med. 2023 May;64(5):744-750.

115. Song H, Ferri V, Duan H, Aparici CM, Davidzon G, Franc BL, Moradi F, Nguyen J, Shah J, **Iagaru A**. SPECT at the speed of PET: a feasibility study of CZT-based whole-body SPECT/CT in the post 177Lu-DOTATATE and 177Lu-PSMA617 setting. Eur J Nucl Med Mol Imaging. 2023 Jul;50(8):2250-2257.

116. Duan H, Davidzon GA, Moradi F, Liang T, Iagaru A. Modified PROMISE Criteria for Standardized Interpretation of Gastrin Releasing Peptide Receptor (GRPR)-targeted PET. Eur J Nucl Med Mol Imaging. 2023 Nov;50(13):4087-4095.

117. Fernández R, Soza-Ried C, **Iagaru A**, Stephens A, Müller A, Schieferstein H, Sandoval C, Amaral H, Kramer V. Imaging GRPr Expression in Metastatic Castration-Resistant Prostate Cancer with [$^{68}$Ga]Ga-RM2-A Head-to-Head Pilot Comparison with [$^{68}$Ga]Ga-PSMA-11. Cancers (Basel). 2023 Dec 29;16(1):173.

118. Wang J, Seo JW, Kare AJ, Schneider M, Tumbale SK, Wu B, Raie MN, Pandrala M, **Iagaru A**, Brunsing RL, Charville GW, Park WG, Ferrara KW. Spatial transcriptomic analysis drives PET imaging of tight junction protein expression in pancreatic cancer theranostics. bioRxiv [Preprint]. 2024 Jan 8:2024.01.07.574209.

119. Duan H, Moradi F, Davidzon GA, Liang T, Song H, Loening AM, Vasanawala S, Srinivas S, Brooks JD, Hancock S, **Iagaru A.** $^{68}$Ga-RM2 PET-MRI versus MRI alone for evaluation of patients with biochemical recurrence of prostate cancer: a single-centre, single-arm, phase 2/3 imaging trial. Lancet Oncol. 2024 Apr;25(4):501-508.

120. Duan H, Song H, Davidzon GA, Moradi F, Liang T, Loening A, Vasanawala S, **Iagaru A.** Prospective Comparison of $^{68}$Ga-NeoB and $^{68}$Ga-PSMA-R2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer. J Nucl Med. 2024 Jun 3;65(6):897-903

121. Song H, Leonio MI, Ferri V, Duan H, Aparici CM, Davidzon G, Franc BL, Moradi F, Shah J, Bergstrom CP, Fan AC, Shah S, Khaki AR, Srinivas S, **Iagaru A.** Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [$^{177}$Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2024 Jul;51(9):2784-2793.

122. Ghezzo S, Bharathi PG, Duan H, Mapelli P, Sorgo P, Davidzon GA, Bezzi C, Chung BI, Samanes Gajate AM, Thong AEC, Russo T, Brembilla G, Loening AM, Ghanouni P, Grattagliano A, Briganti A, De Cobelli F, Sonn G, Chiti A, **Iagaru A**, Moradi F, Picchio M**.** The Challenge of External Generalisability: Insights from the Bicentric Validation of a [$^{68}$Ga]Ga-

PSMA-11 PET Based Radiomics Signature for Primary Prostate Cancer Characterisation Using Histopathology as Reference. Cancers (Basel). 2024 Dec 7;16(23):4103.

123. Wang J, Seo JW, Kare AJ, Schneider M, Pandrala M, Tumbale SK, Raie MN, Engudar G, Zhang N, Guo Y, Zhong X, Ferreira S, Wu B, Attardi LD, Pratx G, **Iagaru A**, Brunsing RL, Charville GW, Park WG, Ferrara KW. Spatial transcriptomic analysis drives PET imaging of tight junction protein expression in pancreatic cancer theranostics. Nat Commun. 2024 Dec 30;15(1):10751.

124. Mehranian A, Wollenweber SD, Bradley KM, Fielding PA, Huellner M, **Iagaru A**, Dedja M, Colwell T, Kotasidis F, Johnsen R, Jansen FP, McGowan DR. Deep learning-based time-of-flight (ToF) enhancement of non-ToF PET scans for different radiotracers. Eur J Nucl Med Mol Imaging. 2025 Jul;52(8):2968-2978.

125. **Iagaru A**, Suarez JF, Behr S, Aggarwal R, Paredes P, Buffi N, Penhoat N, Ceci F, Walz J, Doumerc N, Coulanges M, Xu Z, SeigneC, Wilke C, Catafau AM, Fanti S, Maurer T. Imaging Efficacy of [$^{18}$F] CTT1057 PET for the Detection of PSMA-positive Tumours using Histopathology as Standard of Truth: Results from the GuideView Phase 2/3 Prospective Multicentre Study. J Nucl Med. 2025 Aug 1;66(8):1232-1238.

126. Fanti S, Robles Barba JJ, Behr S, Maurer T, Paredes P, Walz J, Duch J, Perdigo MS, Mainta IC, Benoit Bonnefoy P, Coulanges M, Tang J, Seigne C, Wilke C, Catafau AM, **Iagaru A**, Aggarwal R. Imaging efficacy of [$^{18}$F] CTT1057 PET/CT in patients with biochemically recurrent prostate cancer: results from the GuidePath phase 3, prospective, multicenter study. J Nucl Med. 2025 Aug 1;66(8):1210-1216.

127. Mittra ES, Solnes LB, van der Veldt AAM, Wong J, Aloj L, Heinrich MC, Chen CT, Rowe SP, Brabander T, Pacey S, Aimone P, Pathak D, Blumenstein L, Liu Y, **Iagaru A**. Phase I study of [$^{177}$Lu] NeoB in patients with advanced solid tumors overexpressing gastrin-releasing peptide receptor: Preliminary safety and dosimetry results. J Nucl Med. 2026 Feb 2;67(2):262-268.

***In Press***

1. Park HL, Kersting D, Bergstrom CP, Khaki AR, Shah, J Davidzon GA, Moradi F, Fan A, Shah SA, Grady E, Srinivas S, **Iagaru A**, Song H. Prognostic Value of Same Day Post-Therapy Whole Body SPECT/CT Using Visual RECIP 1.0 During [177Lu]Lu-PSMA-617 Therapy for Metastatic Castration Resistant Prostate Cancer (mCRPC). J Nucl Med. 2026 Feb 2;67(2):262-268.

***Submitted***

1. N/A.

**2. Peer Reviewed Other Journal Articles - Case Reports, Editorials, Invited Commentaries, Appropriate Use Criteria, Reviews (Total 107)**

1. Jadvar H, Bonyadlou S, **Iagaru A**, Colletti P. 18F FDG PET/CT Demonstration of Salivary Glands Involvement in Sjogren's Syndrome. Clin Nucl Med. 2005 Oct;30(10):698-9.
2. **Iagaru A**, Wassef H, Henderson R. Failed Atrial Septal Defect Repair versus Pulmonary Hypertension with Right Ventricular Failure. Clin Nucl Med. 2005 Nov;30(11):767-8.
3. **Iagaru A**, Siegel ME. Demonstration of a Right Inguinal Hernia Containing Urinary Bladder Diverticulum on Whole Body Bone Scan and Pelvic CT. Eur J Nucl Med Mol Imaging. 2006 Feb;33(2):234.
4. **Iagaru A**, Mari C, Segall G. 18F FDG PET Evaluation of Bronchial Plasmacytoma, with CT and MRI Correlation. Clin Nucl Med. 2006 May;31(5):279-80.
5. **Iagaru A**, Gamie S, Segall G. 18F FDG PET Imaging of Urinary Bladder Oat Cell Carcinoma with Widespread Osseous Metastases. Clin Nucl Med. 2006 Aug;31(8):476-8.
6. **Iagaru A**, Henderson R. 18F FDG PET/CT in the Follow-Up of Non-Ossifying Fibroma. AJR Am J Roentgenol. 2006. Sep;187(3):830-2.
7. **Iagaru A**, Hachamovitch R, Colletti PM, Wassef H. Ectopic Mediastinal Parathyroid Adenoma on 99mTc Sestamibi Myocardial Perfusion Scintigraphy. J Nucl Cardiol. 2006 Sep;13(5):719-21.

8. **Iagaru A**, McDougall IR. 18F FDG PET/CT Demonstration of an Adrenal Metastasis in a Patient with Anaplastic Thyroid Cancer. Clin Nucl Med. 2007 Jan;32(1):13-5.
9. **Iagaru A**, Mari C, Gambhir SS. Follicular Dendritic Sarcoma within a Focus of Castleman's Disease. Serial 18F FDG PET/CT in the Follow-Up of Recurrence with Histopathologic Confirmation. Rev Esp Med Nucl. 2007 Jan;26(1):40-5.
10. **Iagaru A**, Gamie S, Segall G. 18F FDG PET Visualization of Urinary Leak Following Nephrostomy Tube Removal. Clin Nucl Med. 2007 Feb;32(2):168-169.
11. **Iagaru A**, McDougall IR. Therapy of Thyrotoxicosis. J Nucl Med. 2007 Mar;48(3):379-89
12. **Iagaru A**, Quon A. Advances in Metabolic Imaging for Surgical Oncology. Surg Oncol Clin N Am. 2007 Apr;16(2):273-92.
13. **Iagaru A**, Chen X, Gambhir SS. Molecular Imaging Can Speed Up Anti-Angiogenic Drug Development. Nat Clin Pract Oncol. 2007 Oct;4(10):556-7.
14. Mittra ES, **Iagaru A**, Quon A, Fischbein N. PET Imaging of Skull Base Neoplasms. PET Clinics. 2007 Oct;2(4):489-510.
15. **Iagaru A**, Peterson D, Quon A, Dutta S, Twist C, Daghighian F, Gambhir SS, Albanese C. Case study: 123I MIBG Mapping with Intraoperative Gamma Probe for Recurrent Neuroblastoma. Mol Imaging Biol. 2008 Jan-Feb;10(1):19-23.
16. **Iagaru A**, Goris ML, Gambhir SS. Perspectives of Molecular Imaging and Radioimmunotherapy in Lymphoma. Radiol Clin North Am. 2008 Mar;46(2):243-252.
17. **Iagaru A**, Goris ML. Rhabdomyosarcoma diffusely metastatic to the bone marrow: suspicious findings on 99mTc-MDP bone scintigraphy confirmed by 18F FDG PET/CT and bone marrow biopsy. Eur J Nucl Med Mol Imaging. 2008 Sep;35(9):1746.
18. Mittra ES, **Iagaru A**. 18F FDG PET and PET/CT for evaluating primary bone tumors. PET Clin. 2010 Jul;5(3):327-40.
19. Mansouri MA, **Iagaru A**. 18F FDG PET/CT Demonstration of Lymphohistiocytic Meningitis. Clin Nucl Med. 2010 Aug;35(8):633-4.
20. Lin F, **Iagaru A**. Current Concepts and Future Directions in Radioimmunotherapy. Curr Drug Discov Technol. 2010 Dec 1;7(4):253-62.
21. **Iagaru A**. 18F-FDG PET/CT: timing for evaluation of response to therapy remains a clinical challenge. Am J Nucl Med Mol Imaging. 2011;1(1):63-4.
22. Mittra ES, **Iagaru A**, Leung A. Case 166: Metastatic Left Pulmonary Artery Sarcoma. Radiology. 2011 Feb;258(2):645-648.
23. McDougall IR, **Iagaru A**. Thyroid Stunning: Fact or Fiction? Seminars in Nuclear Medicine. 2011 Mar;41(2):105-112.
24. Mosci C, **Iagaru A**. PET/CT Imaging of Thyroid Cancer. Clin Nucl Med. 2011 Dec;36(12):e180-5.
25. Guo H, Mosci C, **Iagaru A**. Demonstration of peripheral nerve root involvement by non-Hodgkin's lymphoma on 18F FDG PET/CT. Eur J Nucl Med Mol Imaging. 2012 Apr;39(4):729-30.
26. Mosci C, **Iagaru A**. 18F NaF PET/CT in the Assessment of Malignant Bone Disease. PET Clinics. 2012 Jul;7(3):263-74.
27. Mosci C, McDougall IR, Jeffrey RB, **Iagaru A**. 18F FDG PET/CT Demonstration of a Liver Metastasis in a Patient with Papillary Thyroid Cancer. Clin Nucl Med. 2012 Sep;37(9):e234-6.
28. Delbeke D, Alessio A, **Iagaru A**. Second Sino-American Conference on Nuclear Medicine. J Nucl Med. 2013 Apr;54(4):15N-6N.
29. **Iagaru A**, Gambhir SS. Imaging Tumor Angiogenesis: The Road to Clinical Utility. AJR Am J Roentgenol. 2013 Aug;201(2):W183-91.
30. Kumar M, **Iagaru A**. 18F FDG PET/CT Demonstration of Diffuse Lymphohistiocytic Granulomatous Vasculitis. Clin Nucl Med. 2013 Aug;38(8):e329-30.
31. Keu KV. **Iagaru A**. The Clinical Use of PET/CT in the Evaluation of Melanoma. Methods Mol Biol. 2014;1102:553-80.

32. Jones RP, **Iagaru A**. 18F NaF Brain Metastasis Uptake in a Patient with Melanoma. Clin Nucl Med. 2014 Oct;39(10):e448-50.

33. Mahapatra S, Chin CC, **Iagaru A**, Heerema-McKenney A, Twist CJ. Successful treatment of systemic and central nervous system post-transplant lymphoproliferative disorder without the use of high-dose methotrexate or radiation. Pediatr Blood Cancer. 2014 Nov;61(11):2107-9.

34. Tuttle RM, Haddad RI, Ball DW, Byrd D, Dickson P, Duh QY, Ehya H, Haymart M, Hoh C, Hunt JP, **Iagaru A**, Kandeel F, Kopp P, Lamonica DM, Lydiatt WM, McCaffrey J, Moley JF, Parks L, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ, Hoffmann KG, Hughes M. Thyroid carcinoma, version 2.2014. J Natl Compr Canc Netw. 2014 Dec;12(12):1671-80.

35. Jackson T, Sabbah N, **Iagaru A**. 123I Accumulation in Thoracic Neoesophagus Masking Residual Papillary Thyroid Cancer. Clin Nucl Med. 2015 Feb;40(2):e150-1.

36. Harolds JA, Oates ME, Guiberteau MJ, Ghesani M, Scanlon MH, **Iagaru A**. New training pathways to dual certification in nuclear medicine and radiology. J Nucl Med. 2015 Jun;56(6):17N-18N.

37. Haddad RI, Lydiatt WM, Ball DW, Busaidy NL, Byrd D, Callender G, Dickson P, Duh QY, Ehya H, Haymart M, Hoh C, Hunt JP, **Iagaru A**, Kandeel F, Kopp P, Lamonica DM, McCaffrey JC, Moley JF, Parks L, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Smallridge RC, Sturgeon C, Wang TN, Wirth LJ, Hoffmann KG, Hughes M. Anaplastic Thyroid Carcinoma, Version 2.2015. J Natl Compr Canc Netw. 2015 Sep;13(9):1140-50.

38. **Iagaru A**. 18F-Fluoride PET in the Assessment of Malignant Bone Disease. J Nucl Med. 2015 Oct;56(10):1476-7.

39. Sonni I, **Iagaru A**. PET Imaging Toward Individualized Management of Urologic and Gynecologic Malignancies. PET Clin. 2016 Jul;11(3):261-72.

40. **Iagaru A**, Mittra E, Colletti PM, Jadvar H. Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer. J Nucl Med. 2016 Oct;57(Suppl 3):19S-24S.

41. Mansi R, Minamimoto R, Mäcke H, **Iagaru A**. Bombesin-Targeted PET of Prostate Cancer. J Nucl Med. 2016 Oct;57(Suppl 3):67S-72S.

42. Sonni I, Baratto L, **Iagaru A**. Imaging of Prostate Cancer Using Gallium-68-Labeled Bombesin. PET Clin. 2017 Apr;12(2):159-171.

43. Subramaniam RM, Jadvar H, Colletti PM, Guimaraes A, Gullapali R, **Iagaru A**, McConathy J, Meltzer CC, Nadel H, Noto RB, Packard AB, Rohren EM, Oates ME. ACR and SNMMI Joint Credentialing Statement for PET/MRI of the Body. J Nucl Med. 2017 Jul;58(7):1174-1176

44. **Iagaru A**. Dual-Integrin αvβ3- and Gastrin-Releasing Peptide Receptor-Targeting PET Radiotracer (68Ga-BBN-RGD). J Nucl Med. 2017 Oct;58(10):1706.

45. Gerson JN, Witteles RM, Chang DT, Beygui RE, **Iagaru A**, Kunz PL. Carcinoid Syndrome Complicating a Pancreatic Neuroendocrine Tumor: A Case Report. Pancreas. 2017 Nov/Dec;46(10):1381-1385.

46. Jadvar H, Colletti PM, Delgado-Bolton R, Esposito G, Krause BJ, **Iagaru A**, Nadel H, Quinn DI, Rohren E, Subramaniam RM, Zukotynski K, Kauffman J, Ahuja S, Griffeth L. Appropriate Use Criteria for 18F-FDG PET/CT in Restaging and Treatment Response Assessment of Malignant Disease. J Nucl Med. 2017 Dec;58(12):2026-2037.

47. **Iagaru A**. Will GRPR Compete with PSMA as a Target in Prostate Cancer? J Nucl Med. 2017 Dec;58(12):1883-1884.

48. Yurkiewicz IR, Ganjoo KN, **Iagaru A**. Anaplastic Thyroid Cancer With Extensive Skeletal Muscle Metastases on 18F-FDG PET/CT. Clin Nucl Med. 2018 Apr;43(4):e113-e114.

49. Bradley K, McGowan DR, Gleeson FV, Johnson GB, Young JR, Levin CS, Davidzon GA, **Iagaru A**. Embrace Progress. J Nucl Med. 2018 Jul;59(7):1169.

50. **Iagaru A**, Minamimoto R. Nuclear Medicine Imaging Techniques for Detection of Skeletal Metastases in Breast Cancer. PET Clin. 2018 Jul;13(3):383-393.

51. Baratto L, Jadvar H, **Iagaru A**. Prostate Cancer Theranostics Targeting Gastrin-Releasing Peptide Receptors. Mol Imaging Biol. 2018 Aug;20(4):501-509.

52. Bartelink IH, Jones EF, Shahidi-Latham SK, Rong ELP, Zheng Y, Vicini P, van 't Veer L, Wolf D, **Iagaru A**, Kroetz DL, Prideaux B, Cilliers C, Thurber G, Wimana Z, Gebhart G. Tumor drug penetration measurements could be the neglected piece of the personalized cancer treatment puzzle. Clin Pharmacol Ther. 2019 Jul;106(1):148-163.

53. Laudicella R, Davidzon G, Vasanawala S, Baldari S, **Iagaru A**. 18F-FDG PET/MR Refines Evaluation in Newly Diagnosed Metastatic Urethral Adenocarcinoma. Nucl Med Mol Imaging. 2019 Aug;53(4):296-299.

54. Wangerin KA, **Iagaru A**. Improved Scatter Correction to Eliminate Halo-Artifacts for 68Ga-labeled Radiopharmaceuticals in PET Imaging. J Nucl Med. 2019 Sep;60(9):1334.

55. Wangerin KA, **Iagaru A**. 68Ga Scatter Correction to Eliminate Halo-Artifacts in PET Imaging. Urology. 2019 Sep;131:262.

56. Hope TA, Fayad ZA, Fowler KJ, Holley D, **Iagaru A**, McMillan AB, Veit-Haiback P, Witte RJ, Zaharchuk G, Catana C. Summary of the First ISMRM-SNMMI Workshop on PET/MRI: Applications and Limitations. J Nucl Med. 2019 Oct;60(10):1340-1346.

57. Girod BJ, Guja KE, Davidzon G, Chan F, Zucker E, Franc BL, Moradi F, **Iagaru A**, Aparici CM. Fungal endocarditis resembling primary cardiac malignancy in a patient with B-cell ALL with culture confirmation. Radiol Case Rep. 2019 Nov 19;15(2):117-119.

58. Duan H, Baratto L, **Iagaru A**. The Role of PET/CT in the Imaging of Pancreatic Neoplasms. Semin Ultrasound CT MR. 2019 Dec;40(6):500-508.

59. Laudicella R, Baratto L, Minutoli F, Baldari S, **Iagaru A**. Malignant Cutaneous Melanoma: Updates in PET Imaging. Curr Radiopharm. 2020;13(1):14-23.

60. Seib CD, Chen J, **Iagaru A**. Shifting Trends and Informed Decision-Making in the Management of Graves' Disease. Thyroid. 2020 Mar;30(3):351-354.

61. Maurer AH, Abell T, Bennett P, Diaz JR, Harris LA, Hasler W, **Iagaru A**, Koch KL, McCallum RW, Parkman HP, Rao SSC, Tulchinsky M. Appropriate Use Criteria for Gastrointestinal Transit Scintigraphy. J Nucl Med. 2020 Mar;61(3):11N-17N.

62. Sonni I, Minamimoto R, Baratto L, **Iagaru A**. Response to: Letter to the Editors: Re: Simultaneous PET/MRI in the Evaluation of Breast and Prostate Cancer Using Combined Na[18F] F and [18F]FDG: a Focus on Skeletal Lesions. Mol Imaging Biol. 2020 Apr;22(2):221-222.

63. Baratto L, Duan H, Maecke HR, **Iagaru A**. Imaging the Distribution of Gastrin Releasing Peptide Receptors in Cancer. J Nucl Med. 2020 Jun;61(6):792-798.

64. Kozlov A, Pantel A, **Iagaru A**, Ikeda D. Pulmonary Adenocarcinoma Metastasis to the Breast Unexpectedly Discovered on Re-staging 18F-FDG PET/CT in a Woman with a Normal Screening Mammogram. Clin Lung Cancer. 2020 Jun 19:S1525-7304(20)30206-0.

65. Weinreb J, Choyke P, **Iagaru A**, Ippolito J, Lockhart M, Merrick G, Sachdev S, Silva E 3rd, Taneja SS, Tempany C, Wahl R, Rosenkrantz A. ACR Stakeholder Prostate Summit. J Am Coll Radiol. 2020 Aug;17(8):1068-1070.

66. Moradi F, **Iagaru A**. The Role of Positron Emission Tomography in Pancreatic Cancer and Gallbladder Cancer. Semin Nucl Med. 2020 Sep;50(5):434-446.

67. Ceci F, Castellucci P, Polverari G, **Iagaru A**. Clinical application of Fluciclovine PET, choline PET and gastrin-releasing polypeptide receptor (bombesin) targeting PET in prostate cancer. Curr Opin Urol. 2020 Sep;30(5):641-648.

68. Guja KE, Brown R, Girod B, Song H, Harrison C, Franc BL, Moradi F, Davidzon G, **Iagaru A**, Aparici CM. An unusual presentation of recurrent T cell lymphoma: angiocentric pattern of cutaneous uptake on 18F FDG PET/CT. Eur J Nucl Med Mol Imaging. 2020 Sep 12.

69. Li D, Patel CB, Xu G, **Iagaru A**, Zhu Z, Zhang L, Cheng Z. Visualization of Diagnostic and Therapeutic Targets in Glioma With Molecular Imaging. Front Immunol. 2020 Oct 30;11:592389.

70. Czernin J, **Iagaru A**. Humana and 18F-FDG PET/CT: Another Sequel to the Injustice of Being Judged by the Errors of Others. J Nucl Med. 2021 Jan;62(1):1-2.

71. Moradi F, **Iagaru A**. Will FAPI PET/CT Replace FDG PET/CT in the Next Decade?-Counterpoint: No, not so fast! AJR Am J Roentgenol. 2021 Feb;216(2):307-308.

72. Guja KE, Brown R, Girod B, Song H, Harrison C, Franc BL, Moradi F, Davidzon G, **Iagaru A**, Mari Aparici C. An unusual presentation of recurrent T cell lymphoma: angiocentric pattern of cutaneous uptake on [18F]FDG PET/CT. Eur J Nucl Med Mol Imaging. 2021 Apr;48(4):1256-1257.

73. Kozlov A, Pantel A, **Iagaru A**, Ikeda D. Pulmonary Adenocarcinoma Metastasis to the Breast Unexpectedly Discovered on Re-staging 18F-FDG PET/CT in a Woman With a Normal Screening Mammogram. Clin Lung Cancer. 2021 May;22(3):e438-e441.

74. Tolwani A, Matusiak M, Bui N, Forgó E, Varma S, Baratto L, **Iagaru A**, Lazar AJ, van de Rijn M, Przybyl J. Prognostic relevance of the hexosamine biosynthesis pathway activation in leiomyosarcoma. NPJ Genom Med. 2021 May 3;6(1):30.

75. Franc BL, **Iagaru A**. Letter to the Editor: "Disparities in PET imaging for prostate cancer at a tertiary academic medical center". Nucl Med. 2021 May 10;62(5):747-748.

76. Song H, Guja KE, **Iagaru A**. 18F-FDG PET/CT for Evaluation of Post-Transplant Lymphoproliferative Disorder (PTLD). Semin Nucl Med. 2021 Jul;51(4):392-403.

77. Jha A, Taïeb D, Carrasquillo JA, Pryma DA, Patel M, Millo C, de Herder WW, Del Rivero J, Crona J, Shulkin BL, Virgolini I, Chen AP, Mittal BR, Basu S, Dillon JS, Hope TA, Mari Aparici C, **Iagaru A**, Hicks RJ, Avram AM, Strosberg JR, Civelek AC, Lin FI, Pandit-Taskar N, Pacak K. High-Specific-Activity 131I-MIBG versus 177Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma. Clin Cancer Res. 2021 Jun 1;27(11):2989-2995.

78. Aide N, Lasnon C, Kesner A, Levin CS, Buvat I, **Iagaru A**, Hermann K, Badawi RD, Cherry SR, Bradley KM, McGowan DR. New PET technologies - embracing progress and pushing the limits. Eur J Nucl Med Mol Imaging. 2021 Aug;48(9):2711-2726.

79. **Iagaru A**. 2021 SNMMI Highlights Lecture: General Nuclear Medicine. J Nucl Med. 2021 Aug 1;62(8):12N-17N.

80. Moradi F, **Iagaru A**, McConathy J. Clinical Applications of PET/MR Imaging. Radiol Clin North Am. 2021 Sep;59(5):853-874.

81. Laudicella R, Quartuccio N, Argiroffi G, Alongi P, Baratto L, Califaretti E, Frantellizzi V, De Vincentis G, Del Sole A, Evangelista L, Baldari S, Bisdas S, Ceci F, **Iagaru A**; Young Italian Association of Nuclear Medicine (AIMN) group. Unconventional non-amino acid PET radiotracers for molecular imaging in gliomas. Eur J Nucl Med Mol Imaging. 2021.

82. Moradi F, Farolfi A, Fanti S, **Iagaru A**. Prostate cancer: Molecular imaging and MRI. Eur J Radiol. 2021 Oct;143:109893.

83. Srinivas S, **Iagaru A**. To Scan or Not to Scan: An Unnecessary Dilemma for PSMA Radioligand Therapy. J Nucl Med. 2021 Nov;62(11):1487-1488.

84. Duan H, **Iagaru A**, Mari Aparici C. Radiotheranostics - Precision Medicine in Nuclear Medicine and Molecular Imaging. Nanotheranostics 2022 Jan 1;6(1):103-117.

85. Song H, **Iagaru A**, Rowe SP. 18F DCFPyL PET Acquisition, Interpretation and Reporting: Suggestions Post Food and Drug Administration Approval. J Nucl Med. J Nucl Med. 2022 Jun;63(6):855-859.

86. Haddad RI, Bischoff L, Ball D, Bernet V, Blomain E, Busaidy NL, Campbell M, Dickson P, Duh QY, Ehya H, Goldner WS, Guo T, Haymart M, Holt S, Hunt JP, **Iagaru A**, Kandeel F, Lamonica DM, Mandel S, Markovina S, McIver B, Raeburn CD, Rezaee R, Ridge JA, Roth MY, Scheri RP, Shah JP, Sipos JA, Sippel R, Sturgeon C, Wang TN, Wirth LJ, Wong RJ, Yeh M, Cassara CJ, Darlow S. Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 Aug;20(8):925-951.

87. Song H, Guja KE, **Iagaru A**. PSMA theragnostics for metastatic castration resistant prostate cancer. Transl Oncol. 2022 Aug;22:101438.

88. Duan H, **Iagaru A**. The use of advanced imaging in guiding the further investigation and treatment of primary prostate cancer. Cancer Imaging. 2022 Sep 3;22(1):45.

89. Duan H, **Iagaru A**. PET Imaging Using Gallium-68 (68Ga) RM2. PET Clin. 2022 Oct;17(4):621-629.

90. Duan H, **Iagaru A**. Neuroendocrine Tumor Diagnosis: PET/MR Imaging. PET Clin. 2023 Apr;18(2):259-266.

91. **Iagaru A**. 2022 SNMMI Highlights Lecture: General Nuclear Medicine. J Nucl Med. 2023 May;64(5):671-677.

92. Veit-Haibach P, Ahlström H, Boellaard R, Delgado Bolton RC, Hesse S, Hope T, Huellner MW, **Iagaru A**, Johnson GB, Kjaer A, Law I, Metser U, Quick HH, Sattler B, Umutlu L, Zaharchuk G, Herrmann K. International EANM-SNMMI-ISMRM consensus recommendation for PET/MRI in oncology. Eur J Nucl Med Mol Imaging. 2023 Oct;50(12):3513-3537.

93. Duan H, **Iagaru A**. PSMA PET for Detection of Recurrence. Semin Nucl Med. 2024 Jan;54(1):77-86.

94. Oprea-Lager DE, MacLennan S, Bjartell A, Briganti A, Burger IA, de Jong I, De Santis M, Eberlein U, Emmett L, Fizazi K, Gillessen S, Herrmann K, Heskamp S, **Iagaru A**, Jereczek-Fossa BA, Kunikowska J, Lam M, Nanni C, O'Sullivan JM, Panebianco V, Sala E, Sathekge M, Sosnowski R, Tilki D, Tombal B, Treglia G, Tunariu N, Walz J,

Yakar D, Dierckx R, Sartor O, Fanti S. European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer. Eur Urol. 2024 Jan;85(1):49-60.

95. Khessib T, Jha P, Davidzon GA, **Iagaru A**, Shah J. Nuclear Medicine and Molecular Imaging Applications in Gynecologic Malignancies: A Comprehensive Review. Semin Nucl Med. 2024 Mar;54(2):270-292.

96. Crawford ED, Bryce AH, Hussain MH, Agarwal N, Beltran H, Cooperberg MR, Petrylak DP, Shore N, Spratt DE, Tagawa ST, Antonarakis ES, Aparicio AM, Armstrong AJ, Boike TP, Calais J, Carducci MA, Chapin BF, Cookson MS, Davis JW, Dorff T, Eggener SE, Feng FY, Gleave M, Higano C, **Iagaru A**, Morgans AK, Morris M, Murray KS, Poage W, Rettig MB, Sartor O, Scher HI, Sieber P, Small E, Srinivas S, Yu EY, Zhang T, Koo PJ. Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1. JU Open Plus. 2024 Apr;2(4):e00029.

97. Crawford ED, Bryce AH, Hussain MH, Agarwal N, Beltran H, Cooperberg MR, Petrylak DP, Shore N, Spratt DE, Tagawa ST, Antonarakis ES, Aparicio AM, Armstrong AJ, Boike TP, Calais J, Carducci MA, Chapin BF, Cookson MS, Davis JW, Dorff T, Eggener SE, Feng FY, Gleave M, Higano C, **Iagaru A**, Morgans AK, Morris M, Murray KS, Poage W, Rettig MB, Sartor O, Scher HI, Sieber P, Small E, Srinivas S, Yu EY, Zhang T, Koo PJ. Expert Perspectives on Controversies in Metastatic Castration-Resistant Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2. JU Open Plus. 2024 Apr;2(4):e00032.

98. Guja KE, Ganjoo KN, **Iagaru A**. Molecular Imaging in Soft-tissue Sarcoma: Evolving Role of FDG PET. Semin Nucl Med. 2024 May;54(3):332-339.

99. Pascual TNB, Paez D, **Iagaru A**, Gnanasegaran G, Lee ST, Sathekge M, Buatti JM, Giammarile F, Al-Ibraheem A, Pardo MA, Baum RP, De Bari B, Ben-Haim S, Blay JY, Brink A, Estrada-Lobato E, Fanti S, Golubic AT, Hatazawa J, Israel O, Kiess A, Knoll P, Louw L, Mariani G, Mirzaei S, Orellana P, Prior JO, Urbain JL, Vichare S, Vinjamuri S, Virgolini I, Scott AM. Guiding principles on the education and practice of theranostics. Eur J Nucl Med Mol Imaging. 2024 Jul;51(8):2320-2331.

100. **Iagaru A**, Jacene H. The Age of Theragnostics. PET Clin. 2024 Jul;19(3):xiii.

101. Dalm S, Duan H, **Iagaru A**. Gastrin Releasing Peptide Receptors-targeted PET Diagnostics and Radionuclide Therapy for Prostate Cancer Management: Preclinical and Clinical Developments of the Past 5 Years. PET Clin. 2024 Jul;19(3):401-415.

102. Seifert R, Gafita A, Solnes LB, **Iagaru A**. Prostate-specific Membrane Antigen: Interpretation Criteria, Standardized Reporting, and the Use of Machine Learning. PET Clin. 2024 Jul;19(3):363-369.

103. Bryce AH, Agarwal N, Beltran H, Hussain MH, Sartor O, Shore N, Antonarakis ES, Armstrong AJ, Calais J, Carducci MA, Dorff TB, Efstathiou JA, Gleave M, Gomella LG, Higano C, Hope TA, **Iagaru A**, Morgans AK, Morris DS, Morris MJ, Petrylak DP, Reiter RE, Rettig MB, Ryan CJ, Sellinger SB, Spratt DE, Srinivas S, Tagawa ST, Taplin ME, Yu EY, Zhang T, McKay RR, Koo PJ, Crawford ED. Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024. Cancer. 2025 Jan 1;131(1):e35612.

104. Morgat C, **Iagaru A**, Hindié E. Gastrin-Releasing Peptide Receptor Imaging and Therapy in the Era of Personalized Medicine. J Nucl Med. 2025 Feb 3;66(2):207-208.

105. Laudicella R, Bauckneht M, Burger IA, Cacciola A, Fanti S, Farolfi A, Ficarra V, **Iagaru A**, Liberini V, Pergolizzi S, Santo G, Virgolini I, Minutoli F, Baldari S. The role of PSMA-based radioligand therapy in hormone-sensitive prostate cancer. Eur J Nucl Med Mol Imaging. 2025 Jun;52(7):2723-2735.

106. Morgat C, Duan H, Dalm S, Hindié E, Günther T, Krause BJ, Kramer V, Cavelier F, Stephens AW, Moran S, Lamb L, **Iagaru A**. A Vision for Gastrin-Releasing Peptide Receptor Targeting for Imaging and Therapy: Perspective from Academia and Industry. J Nucl Med. 2025 Aug 1;66(8):1160-1167.

107. Callaud A, Duan H, Hindié E, Morgat C, **Iagaru A.** GRPR Expression in Metastatic Cancers: A Review of Potential Application of GRPR-Radioligand Therapy. Semin Nucl Med. 2025 Aug 11:S0001-2998(25)00091-1.

108. Mohseninia N, Eisazadeh R, Mirshahvalad SA, Zamani-Siahkali N, Hörmann AA, Pirich C, **Iagaru A**, Beheshti M. Diagnostic Value of Gastrin-Releasing Peptide Receptor-Targeted PET Imaging in Oncology: A Systematic Review. Semin Nucl Med. Semin Nucl Med. 2025 Sep;55(5):776-788.

109. Noamen H, Cras Y, Garcia C, Song H, **Iagaru A**, Deandreis D. 3D-ring CZT gamma cameras in theranostics: is it a revolution? EJNMMI Rep 2026 May 5.

**3. Book Chapters**

1. **Iagaru A**. Nuclear Medicine. In: Uzelac A, Davis R, eds. Blueprints Radiology, 2nd Edition. Lippincott Williams & Wilkins, Nov 2005.
2. **Iagaru A**, McDougall IR. Thyroid Imaging: Nuclear Medicine Techniques. In: Wass J, Shalet S, eds. Oxford Textbook of Endocrinology and Diabetes, 2nd Edition. Oxford University Press
3. Keu KV, **Iagaru A**. The Pre-Clinical and Clinical Use of PET/CT in the Evaluation of Melanoma. In: Thurin M, Marincola F, eds. Molecular Diagnostics for Melanoma. Humana Press.
4. **Iagaru A**, McDougall IR. PET/CT in Lymphoma of the Thyroid. In: Wartofsky L, Van Nostrand D, eds. Thyroid Cancer: a Comprehensive Guide to Clinical Management, 2nd Edition. Humana Press.
5. **Iagaru A**, McDougall IR. PET/CT in Follicular Cancer Including Hörthle Cell Cancer. In: Wartofsky L, Van Nostrand D, eds. Thyroid Cancer: a Comprehensive Guide to Clinical Management, 2nd Edition. Humana Press.
6. **Iagaru A**, McDougall IR. PET/CT in Anaplastic Cancer of the Thyroid. In: Wartofsky L, Van Nostrand D, eds. Thyroid Cancer: a Comprehensive Guide to Clinical Management, 2nd Edition. Humana Press.
7. **Iagaru A**, McDougall IR. PET/CT in Medullary Thyroid Cancer. In: Wartofsky L, Van Nostrand D, eds. Thyroid Cancer: a Comprehensive Guide to Clinical Management, 2nd Edition. Humana Press.
8. Sonni I, Garibotto V, Das D, **Iagaru A**, Tarik F. Massoud. PET/MRI in Brain Tumors. In: Iagaru A, Hope TA, Veit-Haibach P, eds. PET/MRI in Oncology. Springer.
9. Sonni I, Baratto L, Freitag MT, Giesel F, Eiber M, **Iagaru A**. PET/MRI in Prostate Cancer. In: Iagaru A, Hope TA, Veit-Haibach P, eds. PET/MRI in Oncology. Springer.
10. Minamimoto R, Taviani V, Vasanawala S, **Iagaru A**. Whole-body PET/MRI Applications in Oncology. In: Iagaru A, Hope TA, Veit-Haibach P, eds. PET/MRI in Oncology. Springer.
11. Jurcic GC, Wong JYC, Knox SJ, Wahl DR, Rosenblat TL, Baratto L, **Iagaru A**, Meredith RF, Ha CS. Targeted Radionuclide Therapy. In Tepper J, ed. Clinical Radiation Oncology, Elsevier.
12. Moradi F, Brunsing RL, Sheth VR, **Iagaru A**. Positron Emission Tomography – Magnetic Resonance Imaging. In Ross, BD, Gambhis SS, eds. Molecular Imaging Principles and Practice, 2nd Edition, Elsevier.

**4. Books**

1. **Iagaru A**, Hope TA, Veit-Haibach P, eds. *PET/MRI in Oncology.* Springer (2018).

**5. Presentations**

***Invited Presentations***

1. $^{18}$F FDG PET/CT in the Management of Ovarian Carcinoma. PAVAHCS PET/CT Symposium, Palo Alto, CA. Mar 24, 2007.
2. $^{18}$F FDG PET/CT Assessment of Patients with Thyroid Cancer. PAVAHCS PET/CT Symposium, Palo Alto, CA. Mar 24, 2007.
3. Radiation Therapy Planning for GI Cancers: When Can $^{18}$F FDG PET/CT Evaluation Provide Useful Information? RSNA Annual Meeting, Chicago, IL. Nov 28, 2007.
4. Sarcomas: Classification, Diagnosis and Therapeutic Approaches, with an Emphasis on the Role of $^{18}$F FDG PET/CT. Society of Nuclear Medicine, Northern California Chapter Annual Meeting, Pleasanton, CA. Feb 28, 2008.
5. $^{18}$F Sodium Fluorine: An Unfinished Business. MIPS Seminar Series, Stanford, CA. Nov 17, 2008.
6. Old Tracers, New Ideas: Clinical Research in Nuclear Medicine. Nuclear Medicine Grand Rounds. Stanford, CA. Nov 18, 2008.
7. The Physiology of $^{18}$F FDG and Principles of PET Scanning. 4th Stanford PET/CT Symposium, Las Vegas, NV. Feb 12, 2009.
8. Vascular Tracer Activity: Disease or Not? 4th Stanford PET/CT Symposium, Las Vegas, NV. Feb 13, 2009.

9. PET/CT as an Adjunctive Test for Infectious or Inflammatory Disease? 4th Stanford PET/CT Symposium, Las Vegas, NV. Feb 13, 2009.
10. Bexxar® and Zevalin® Radioimmunotherapy in Non-Hodgkin Lymphomas. Stanford Nuclear Medicine Stampede, Stanford, CA. Mar 21, 2009.
11. Novel Strategies for PET/CT Imaging in Oncology. Medical Oncology Grand Rounds. Stanford, CA. Nov 10, 2009.
12. Updates on PET/CT and Thyroid Cancer. 5th Stanford PET/CT Symposium, Las Vegas, NV. Feb 11, 2010.
13. $^{99m}$Tc-MDP Scintigraphy vs. $^{18}$F NaF PET/CT vs. $^{18}$F FDG PET/CT for Detection of Skeletal Metastases. 5th Stanford PET/CT Symposium, Las Vegas, NV. Feb 12, 2010.
14. Whole Body MRI vs. PET: Is PET Still Best for Oncology? 5th Stanford PET/CT Symposium, Las Vegas, NV. Feb 13, 2010.
15. An Integrated Approach for the Early Detection of Cancer. 5th Stanford PET/CT Symposium, Las Vegas, NV. Feb 13, 2010.
16. Updates on PET/CT and Thyroid Cancer. Nuclear Medicine Grand Rounds. Stanford, CA. Apr 6, 2010.
17. Introduction to PET/CT. Hospital Mae de Deus Symposium, Porto Alegre, Brazil. Apr 26, 2010.
18. Lymphomas: What Can Nuclear Medicine Do for You? Medical Oncology Grand Rounds. Stanford, CA. Nov 16, 2010.
19. Imaging Angiogenesis: What Can Different Modalities Do? PET/CT in Angiogenesis Imaging. RSNA Annual Meeting, Chicago, IL. Dec 2, 2010.
20. $^{18}$F FPPRGD$_2$: A Novel PET Radiopharmaceutical for Imaging Breast Cancer. Breast Disease Management Group Grand Rounds. Stanford, CA. Apr 1, 2011.
21. Bexxar® and Zevalin® Radioimmunotherapy in Non-Hodgkin Lymphomas: Clinical Results. SNM Annual Meeting, San Antonio, TX. Jun 4, 2011.
22. Practical Considerations and Clinical Applications of Radioimmunotherapy. Society of Nuclear Medicine, Northern California Chapter Annual Meeting, Pleasanton, CA. Feb 23, 2012.
23. Beyond FDG: Novel Clinical PET Radiopharmaceuticals. 17$^{th}$ Nuclear Medicine Annual Meeting, Coimbra, Portugal. Apr 25, 2012.
24. Novel PET Tracers and Their Future Use in Assessment of Response to Treatment. ASCO Annual Meeting, Chicago, IL. Jun 1-5, 2012 (Session Organizer and Co-Chair).
25. SPECT/CT in Thyroid and Parathyroid Diseases. SNM Annual Meeting, Miami, FL. Jun 9-13, 2012 (Session Organizer and Moderator).
26. $^{18}$F NaF PET/CT and $^{18}$F FDG PET/CT: What is Their Role in the Management of Bone Malignancy? SNM Annual Meeting, Miami, FL. Jun 9-13, 2012 (Session Organizer and Moderator).
27. Thyroid Imaging and Therapy for the Lay Person. SNM Annual Meeting, Miami, FL. Jun 9-13, 2012.
28. Molecular Imaging in the Assessment and Follow-Up of Breast Cancer. Society of Nuclear Medicine of Puerto Rico Annual Meeting, Rio Grande, PR. Oct 12-14, 2012.
29. $^{18}$F NaF PET/CT and $^{18}$F FDG PET/CT: What is Their Role in the Management of Bone Malignancy? Society of Nuclear Medicine of Puerto Rico Annual Meeting, Rio Grande, PR. Oct 12-14, 2012.
30. Society of Nuclear Medicine & Molecular Imaging and Chinese Society of Nuclear Medicine 2$^{nd}$ Sino-American Conference, New Orleans, LA. Jan 23-27, 2013 (Organizer and Co-Chair).
31. Radionuclide Therapy of Painful Bone Metastases: Past, Present, Future. Society of Nuclear Medicine, Northern California Chapter Annual Meeting, Pleasanton, CA. Feb 28, 2013.
32. Radionuclide Therapy of Painful Bone Metastases: Past, Present, Future. American Urological Association Annual Meeting, San Diego, CA. May 4-8, 2013. (Plenary Session)
33. Radionuclide Therapy of Painful Bone Metastases: Past, Present, Future. Medical Oncology Grand Rounds. Stanford, CA. May 14, 2013.
34. Update of Nuclear Medicine Imaging of Prostate Cancer. Urology Grand Rounds. Stanford, CA. Jun 4, 2013.
35. PET/CT in Clinical Practice: Evidence-based Use and Appropriateness Criteria. ASCO Annual Meeting, Chicago, IL. May 31 - Jun 4, 2013 (Session Organizer and Co-Chair; Speaker).

36. Molecular Imaging in Breast Cancer - Present and Future. SNMMI Annual Meeting, Vancouver, BC. Jun 8-12, 2013 (Session Organizer and Moderator; Speaker).
37. $^{18}$F NaF PET/CT in the Evaluation of Skeletal Malignancy (Primary and Metastatic Disease). SNMMI Annual Meeting, Vancouver, BC. Jun 8-12, 2013 (Session Organizer and Moderator; Speaker).
38. PET/CT Imaging of Angiogenesis. Stanford University and Peking University Joint Symposium, Beijing. Apr 15, 2014 (Organizer; Speaker).
39. From Time-of-Flight PET/CT to Time-of-Flight PET/MRI: Stanford Experience. Chinese Society of Nuclear Medicine and CFMA Spring Meeting, Shenzhen, China. Apr 17-20, 2014 (Keynote Speaker).
40. PET/MRI: The Next Stop for Imaging Angiogenesis in Brain and Breast Cancers. SNMMI Annual Meeting, St Louis, MO. Jun 7-11, 2014 (Session Organizer; Speaker).
41. Bone Scintigraphy in the Management of Patients with Metastatic Castrate-Resistant Prostate Cancer. SNMMI Annual Meeting, St Louis, MO. Jun 7-11, 2014 (Session Organizer and Moderator; Speaker).
42. Differentiating Benign from Malignant Bone Disease: The Role of PET/CT. SNMMI Annual Meeting, St Louis, MO. Jun 7-11, 2014.
43. Imaging Angiogenesis with PET: Radiopharmaceuticals, Opportunities, and Controversies. SNMMI Annual Meeting, St Louis, MO. Jun 7-11, 2014.
44. Clinical Translation of PET/MRI: Stanford Experience. Stanford University and Peking Union Medical College Joint Symposium, Beijing. Sep 14, 2014.
45. PET Imaging: From Bench to Bedside. St. Mary - Catholic University Molecular Imaging Symposium, Seoul, Korea. Sep 16, 2014.
46. Site Readiness and Challenges for Large Clinical Trials. WMIS Annual Congress, Seoul, Korea. Sep 17-20, 2014.
47. From PET/CT to PET/MRI: Initial Experience with SUV Measurements Using the First TOF Simultaneous PET/MRI Scanner. EANM Annual Congress, Stockholm, Sweden. Oct 18-22, 2014.
48. From PET/CT to PET/MRI: Initial Experience with SUV Measurements Using the First TOF Simultaneous PET/MRI Scanner. WRSNM Annual Meeting, Seattle, WA. Oct 30 - Nov 2, 2014.
49. Clinical PET Innovations: Simultaneous TOF PET/MR and Fully-convergent PET reconstruction. RSNA Annual Meeting, Chicago, IL. Nov 30 - Dec 5, 2014.
50. $^{18}$F NaF: 2015 Updates. SNMMI Mid-Winter Meeting, San Antonio, TX. Jan 22-25, 2015.
51. Current Status of $^{18}$F NaF PET/CT. Los Angeles Radiological Society Annual Meeting, Los Angeles, CA. Feb 21-22, 2015.
52. PET/MRI Case Review. Los Angeles Radiological Society Annual Meeting, Los Angeles, CA. Feb 21-22, 2015.
53. PET/MRI Future Directions: Oncology. ISMRM&SNMMI Joint Symposium at the SNMMI Annual Meeting, Baltimore, MD. Jun 6-10, 2015 (Session Organizer and Moderator; Speaker).
54. PET Imaging for Prostate Cancer in the United States: Beyond $^{18}$F FDG and $^{18}$F NaF. WRSNM Annual Meeting, Monterey, CA. Oct 22-25, 2015.
55. Advanced Molecular Imaging and PET: A New Era of Personalized and Precision Medicine. Japanese Society of Nuclear Medicine Annual Meeting, Tokyo, Japan. Nov 5-7, 2015.
56. From PET/CT to PET/MRI: Initial Clinical Experience at Stanford. Japanese Society of Nuclear Medicine Annual Meeting, Tokyo, Japan. Nov 5-7, 2015.
57. PET/MRI at Stanford: Initial Clinical Experience and Future Directions. Peking Union Medical College International Forum on Frontier Technology, Beijing, China. Nov 15, 2015.
58. Anti-Angiogenesis Treatment: Can PET Predict Response Early and Accurately? SNMMI Mid-Winter Meeting, Orlando, FL. Jan 28-31, 2016.
59. $^{18}$F NaF PET in Prostate Cancer: 2016 Updates. High Country Nuclear Medicine Annual Conference, Vail, CO. Feb 27 - Mar 2, 2016.
60. How to Get Away with PET+MRI. 4$^{th}$ Theranostics World Congress, Melbourne, Australia. Nov 7-9, 2016.

61. Imaging the Expression of Gastrin Releasing Peptide Receptors in Prostate Cancer Using Ga-68 Labeled Antagonists. 4th Theranostics World Congress, Melbourne, Australia. Nov 7-9, 2016.
62. The Current Status of PET+MRI in the United States, Its Future Outlook and What to be Expected. Osaka Advanced Imaging Medical Research Group Annual Meeting, Osaka, Japan. Feb 18-19, 2017.
63. Oncological PET+MRI in the United States. Advanced Imaging Symposium, Shenyang, China. May 6, 2017.
64. PET Imaging of Cardiac Sarcoidosis: Current Status and Future Directions. SNMMI Annual Meeting, Denver, CO. Jun 10-14, 2017.
65. SPECT/CT in Endocrinology. SNMMI Annual Meeting, Denver, CO. Jun 10-14, 2017.
66. Updates in Molecular Imaging of Prostate Cancer: Newly Approved and Promising PET Radiopharmaceuticals. Western Regional SNMMI Annual Meeting, Vancouver, BC. Nov 3-5, 2017.
67. Current Status and Future Trends for Future Use of PET+MRI in the United States. Western Regional SNMMI Annual Meeting, Vancouver, BC. Nov 3-5, 2017.
68. PSMA and GRPR Ligands as New and Emerging Prostate Cancer Imaging Agents and Theranostics. RSNA Annual Meeting, Chicago, IL. Nov 26 - Dec 1, 2017.
69. How to Read: $^{68}$Ga-DOTA-TATE PET Scan. Northern California SNMMI Annual Meeting. Feb 22, 2018.
70. Creating Probes for Theranostics. World Federation of Nuclear Medicine and Biology. Apr 23, 2018 (Plenary Session).
71. Imaging in Prostate Cancer. Stanford Cancer Institute Urologic Oncology. May 16, 2018.
72. State-of-the-Art Lecture: Molecular Imaging in GU Malignancies. American Urological Association Annual Meeting. May 21, 2018.
73. PET Imaging and Theranostics in Prostate Cancer. Stanford Urology Grand Rounds. Jun 5, 2018.
74. Non-PSMA Prostate Cancer Theranostics. SNMMI Annual Meeting, Philadelphia, PA. Jun 23, 2018.
75. $^{68}$Gallium Imaging and Related Theranostics: Experience From a Center in the United States. SNMMI Annual Meeting, Philadelphia, PA. Jun 26, 2018.
76. Nuclear Techniques in Infiltrative Diseases: Amyloid and Sarcoid Imaging. ASNC Annual Meeting, San Francisco, CA. Sep 9, 2018.
77. Molecular Imaging and Theranostics in Oncology: Learning from Failures and Advancing Patient Care. UAB Molecular Imaging Symposium, Birmingham, AL. Oct 24, 2018.
78. Novel PET Imaging in Prostate Cancer. RSNA Annual Meeting, Chicago, IL. Nov 27, 2018.
79. Molecular Imaging and Theragnostics in Oncology: Learning from Challenges and Delivering on Promises. NIH, Bethesda, MD. Dec 10, 2018.
80. Prostate Cancer: Molecular Imaging Updates. Los Angeles Radiological Society Annual Meeting, Los Angeles, CA. Feb 9, 2019.
81. Gastrin-Releasing Peptide Receptors for Theranostics in Prostate Cancer. Theranostics World Congress, Jeju, South Korea. Mar 2, 2019.
82. Novel Imaging and Treatments in Neuroendocrine Tumors. ASTRO Multidisciplinary Thoracic Cancers Symposium, San Diego, CA. Mar 15, 2019.
83. How to Get Away with PET+MRI. University of Maryland Radiology Grand Rounds, Baltimore, MD. Mar 27, 2019.
84. Next generation of SSTR imaging. NANETS Multidisciplinary NET Medical Symposium, Boston, MA. Oct 3-5, 2019.
85. Current Landscape of Diagnostic Molecular Imaging of Prostate Cancer in the United States. AdMeTech Annual Global Summit on Precision Diagnosis and Treatment for Prostate Cancer, Boston, MA. Oct 3-5, 2019.
86. Neuroendocrine Theragnostics. 2019 Western Region SNM Annual Meeting, Tucson, AZ. November 1-3, 2019.
87. Landscape of New and Future PET Tracers for Prostate Cancer. RSNA Annual Meeting, Chicago, IL. Dec 1-6, 2019.
88. Gastrin Releasing Peptide Receptors: When in the Course of Prostate Cancer Will They Be Useful? RSNA Annual Meeting, Chicago, IL. Dec 1-6, 2019.
89. Fluciclovine/PSMA Cases. RSNA Annual Meeting, Chicago, IL. Dec 1-6, 2019.

90. Research PET Radiopharmaceuticals in Prostate Cancer: PSMA and Beyond. Los Angeles Radiological Society Annual Meeting, Los Angeles, CA. Feb 8, 2020.

91. GRPR Theragnostics. SNMMI Virtual Annual Meeting, Jul 11-14, 2020.

92. Bench to Bedside Molecular Imaging: Lessons Learned from Standing on the Shoulders of Giants. WRSNMMI Annual Meeting (virtual), Oct 3-4, 2020.

93. Fluciclovine/PSMA Cases. RSNA Annual Meeting, Chicago, IL. Nov 29 – Dec 5, 2020.

94. State-of-the-Art SPECT Technology and Future Directions. High Country Nuclear Medicine Annual Meeting (virtual), Mar 6-7, 2021.

95. Where Are We After 7+ Years of PET/MR and Where Are We Going (in Oncology)? Israeli Society of Nuclear Medicine Annual Meeting (virtual), Mar 21-22, 2021.

96. Molecular Imaging in Prostate Cancer: PSMA is Here, What (if Anything) Next? Frontiers in Cancer Clinical Translation 2021 Seminar Series, Stanford Cancer Institute (virtual), Mar 9, 2021.

97. PET/MRI-Guided Diagnosis and Treatment in Prostate Cancer. AdMeTech 5th Annual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer (virtual), Sep 23-25, 2021.

98. PSMA PET: Advancing Precision Medicine for Prostate Cancer. OHSU Knight Cancer Institute (virtual), Sep 30, 2021.

99. PSMA PET Molecular Imaging in Prostate Cancer Post-FDA Approval of $^{18}$F DCFPyL. MGH Department of Radiology Grand Rounds (virtual), Oct 26, 2021.

100. Brief Introduction to PSMA PET. RSNA Annual Meeting, Chicago, IL. Nov 28 – Dec 2, 2021.

101. Molecular Imaging in Prostate Cancer Post-FDA Approval of $^{18}$F-DCFPyL and $^{68}$Ga-PSMA11: What (if Anything) Else? University of Washington Department of Radiology Grand Rounds (virtual), Jan 26, 2022.

102. An Academic Institution Experience Bringing PSMA PET to the US: 2015 – 2021. 7Th International Conference on Radiation Medicine (virtual), Feb 13-17, 2022.

103. Opening the Theragnostics Clinic: Lessons Learned. 7Th International Conference on Radiation Medicine (virtual), Feb 13-17, 2022.

104. From Theragnostics to PET-Guided Radiotherapy: Renewing Collaborations between Nuclear Medicine and Radiation Oncology. Global Center for Biomedical Science and Engineering, 8th GCB Biomedical Science and Engineering Symposium (virtual), March 21-22, 2022.

105. Infrastructure Requirements for Nuclear Medicine. SNMMI Patient Access Summit, Washington, DC. March 22-23, 2022.

106. Beyond PSMA in Prostate Cancer - Quo Vadis, GRPR? MSKCC Department of Radiology Grand Rounds, New York, NY. Apr 18, 2022.

107. The Theragnostics Age in Nuclear Medicine: Here and Now. Institut Jules Bordet Theragnostics Opening Ceremony, Brussels, Belgium. Apr 27, 2022.

108. A Bright Future for Nuclear Medicine: Theragnostics and Beyond. ANZSNM Annual Meeting, Brisbane, Australia. May 13-15, 2022.

109. $^{18}$F NaF PET: Past, Present (and Future). ACNM-SNMMI Webinar, May 24, 2022.

110. Beyond PSMA in Prostate Cancer - Quo Vadis, GRPR? MIPS Webinar, May 25, 2022.

111. Lessons Learned in 8+ Years of PET/MRI at Stanford University. OHSU Department of Radiology Visiting Professor Lecture, Jun 1, 2022.

112. GRPR PET: Where Are We and Where Are We Going? SNMMI Annual Meeting, Vancouver, BC. Jun 11-14, 2022.

113. A Decade Plus of GRPR PET: Where Are We and Where Are We Going? 6th World Theragnostics Congress, Bad Berka, Germany. Jun 24-26, 2022.

114. The Role of GRPR in Prostate Cancer. WARMTH – 17th ICRT, Kyoto, Japan. Sep 7, 2022.

115. SPECT/CT for 21st Century Molecular Imaging. WFNMB Congress, Kyoto, Japan. Sep 7-11, 2022.

116. Theranostics - More Than Just the Future of Nuclear Medicine. EANM Annual Congress, Barcelona, Spain. Oct 15-19, 2022.

117. Functional imaging of Prostate Cancer: Focus on $^{18}$F-DCFPyL. SNMMI Mid-Winter Meeting, San Francisco, CA. Jan 26-28, 2023.

118. PET/MRI in Prostate Cancer: PSMA and Beyond. SNMMI Mid-Winter Meeting, San Francisco, CA. Jan 26-28, 2023.

119. Biochemical Recurrence in Prostate Cancer: The Evolving Role of Nuclear Medicine. EANM Focus 5 Meeting, Seville, Spain. Feb 2-4, 2023.

120. Molecular Imaging in Prostate Cancer. UMMC Nuclear Medicine Updates 2023, Jackson, MS. Feb 18-19, 2023.

121. 75 Years of Nuclear Medicine at Stanford: History, Lessons Learned and a Glimpse into the Future, 10$^{Th}$ Balkan Congress of Nuclear Medicine, Bucharest, Romania. Mar 15-18, 2023.

122. A Decade Plus of GRPR PET: Where Are We and Where Are We Going? IASNM Radiant Flashpoints Educational Web- Series. Apr 1, 2023.

123. Theragnostics And Beyond. British Nuclear Medicine Society Spring Meeting, Harrogate, UK. May 22-25, 2023.

124. Nuclear Medicine Residency Training: United States. IAEA Theragnostics Training Guidance Meeting, Vienna, Austria. May 29-Jun 2, 2023.

125. How to Evaluate GRPR PET for GRPR-Based Therapies. SNMMI Annual Meeting, Chicago, IL. Jun 24-27, 2023.

126. A Decade of PET/MRI: Where Are We and Where Are We Going? SNMMI Annual Meeting, Chicago, IL. Jun 24-27, 2023.

127. SPECT at the Speed of PET: Imaging $^{177}$Lu Labeled Therapies with CZT Scanners. SNMMI Annual Meeting, Chicago, IL. Jun 24-27, 2023.

128. The Therapy Tsunami – Are we ready? SNMMI Annual Meeting, Chicago, IL. Jun 24-27, 2023.

129. Molecular and Multi-Modality Imaging: Predictive Value. AdMeTech Foundation 7$^{th}$ Global Summit on Precision Diagnosis and Treatment of Prostate Cancer (virtual). Sep 21-23, 2023.

130. Molecular Imaging in GEP NET. SNMMI Therapeutics Conference, Baltimore, MD. Sep 21-23, 2023.

131. Molecular Imaging in Precision Oncology. Binaytara Foundation Precision Oncology Summit, San Francisco, CA. Oct 7-8, 2023.

132. SNMMI Centers of Excellence. 3$^{rd}$ ICPO Forum for Theranostics in Precision Oncology, Garching, Germany. Oct 12-13, 2023.

133. PSMA Therapy. RSNA Annual Meeting, Chicago, IL. Nov 26-30, 2023.

134. Stanford Nuclear Medicine: History, Present and What Waits for Us Beyond Theragnostics. Gustave Roussy Cancer Research Lectures, Paris, France. Feb 16, 2024.

135. Fibroblast Activation Protein-α (FAP) Imaging in Other GI Malignancies. Tata Memorial Centre XXII Annual Conference Evidence Based Management of Cancers in India, Mumbai, India. Mar 1-3, 2024.

136. MIBG Therapy and PRRT in Neuroblastoma. Tata Memorial Centre XXII Annual Conference Evidence Based Management of Cancers in India, Mumbai, India. Mar 1-3, 2024.

137. From Bench to Bedside: The Impact of Nuclear Medicine and Molecular Imaging on Patient Care in Oncology. 1$^{st}$ Gambhir Symposium on Radiochemistry, Molecular Imaging and Theragnostics, Stanford, CA. Mar 11-12, 2024.

138. A Decade Plus of GRPR PET: Where Are We and Where Are We Going? 7$^{th}$ World Theragnostics Congress, Santiago, Chile. Mar 22-24, 2024.

139. Best Examples of Systematic Agent Decisions that Balance Quality and Quantity of Life. AUA Annual Meeting, San Antonio, TX. May 3-6, 2024.

140. Stanford Nuclear Medicine: History, Present and What Waits for Us Beyond Theragnostics. 19$^{th}$ Congress of the Portuguese Society of Nuclear Medicine, Lisbon, Portugal. May 9-11, 2024.

141. (Late Phase) Trials in Oncologic Imaging. SNMMI Annual Meeting, Toronto, Canada. Jun 8-11, 2024.

142. PSMA Therapy. RSNA Annual Meeting, Chicago, IL. Dec 1-4, 2024.

143. PSMA-Targeted Theranostics: Focus on Clinical Applications and Future Perspectives. Nuclear Medicine Update 2025, Nuclear Medicine Society (Singapore), Singapore. Feb 6-9, 2025.

144. Monitoring of patients on PSMA-radioligand therapy. Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics, Lugano, Switzerland. Feb 27-28, 2025.

145. Prostate Cancer: Is There Anything Beyond PSMA? 39th Annual Daniel R. Biello Memorial Lecture, Mallinckrodt Institute of Radiology, St. Louis, MO. Mar 21, 2025.

146. When should we use FDG PET? UCLA UCSF PSMA and Beyond Conference, Los Angeles, CA. Mar 28-29, 2025.

147. GRPR and other peptides for targeting prostate cancer. UCLA UCSF PSMA and Beyond Conference, Los Angeles, CA. Mar 28-29, 2025.

148. FDG PET of the Lymphatic System: Lymphoma, Metastases, and Malignancy Mimics. 2025 Hoag Annual Oncologic PET/CT and Molecular Imaging Course, Huntington Beach, CA. Apr 2-4, 2025.

149. PSMA-targeted PET for Prostate Cancer: How to use it. How to read it. 2025 Hoag Annual Oncologic PET/CT and Molecular Imaging Course, Huntington Beach, CA. Apr 2-4, 2025.

150. Whole-Body SPECT/CT Post 177Lu-Labeled Therapies. SNMMI Annual Meeting, New Orleans, LA. Jun 21-24, 2025.

151. RPT - International Overview and Discussion. SNMMI Annual Meeting, New Orleans, LA. Jun 21-24, 2025.

152. Radiation Dosimetry for Radiopharmaceuticals. ASTRO Annual Meeting, San Francisco, CA. Sep 27-Oct 1, 2025.

153. Bringing Theragnostics to the Clinic: Main Clinical Issues. EANM Annual Congress, Barcelona, Spain. Oct 4-8, 2025.

154. Bench to Bedside in Academia: Lessons Learned and Planning the Next Generation Radiopharmaceuticals. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA. Oct 22-26, 2025.

155. Patient selection for RLT (Lu177 PSMA) and assessment of response. International Conference on Radiopharmaceutical Therapy, Limassol, Cyprus. Nov 6-9, 2025.

156. Post Therapy Imaging SPECT/PET. Western Region Society of Nuclear Medicine Annual Meeting, Honolulu, HI. Nov 14-16, 2025.

157. Advances of GRPR PET Imaging in Prostate Cancer. 6th Theranostics World Congress, Cape Town, South Africa. Jan 29 – Feb 1, 2026.

158. Combination Therapy: $^{177}$Lu-PSMA & $^{223}RaCl_2$: 6th Theranostics World Congress, Cape Town, South Africa. Jan 29 – Feb 1, 2026.

159. Current Developments in Molecular Imaging for Diagnosis and Response Assessment. 13th International Symposium of Targeted Alpha Therapy (TAT 13) / 19th Edwaldo Camargo Symposium - Beta Therapy, Rio de Janeiro, Brazil. Apr 14-16, 2026.

160. Radioligand Therapies in Renal Cell Carcinoma. SWOG Cancer Research Network Spring Meeting, San Francisco, CA. Apr 30 – May 2, 2026.

161. Beyond PSMA PET/CT: The emerging role of PET/MRI in prostate cancer. Portuguese Congress of Oncological Urology, Figueira da Foz, Portugal. May 8-9, 2026.

***Other Presentations (selected)***

1. Iagaru A, Kundu R, Jadvar H, Nagle D. Does 18F FDG PET Change the Staging or Surgical Management of Anal Carcinoma? ACNP Annual Meeting, San Diego, CA. Jan 16-19, 2005.
2. Iagaru A. PET/CT Challenges. Conjoint Southern Pacific Society of Nuclear Medicine and Los Angeles Radiological Society Spring Meeting, Los Angeles, CA. May 14, 2005.
3. Iagaru A, Chawla SP, Menendez LR, Conti PS. The Role of 18F FDG PET and CT in Detection of Pulmonary Metastases from Musculoskeletal Sarcomas. SNM Annual Meeting, Toronto, Canada. Jun 18-22, 2005.
4. Iagaru A, Masamed R, Singer PA, Conti PS. Detection of Occult Medullary Thyroid Cancer with 18F FDG PET and PET/CT. RSNA Annual Meeting, Chicago, IL. Nov 27 - Dec 2, 2005.
5. Iagaru A, Quon A, Goris ML, McDougall IR, Gambhir SS. Merkel Cell Carcinoma: Is There a Role for 18F FDG PET/CT? AMI Annual Conference, Orlando, FL. Mar 25-29, 2006.

6. Iagaru A, Quon A, Ikeda D, Daniel B, Goris ML, McDougall IR, Gambhir SS. Comparison of Mammography, Breast MRI and 18F FDG PET/CT for Breast Cancer Detection. AMI Annual Conference, Orlando, FL. Mar 25-29, 2006.
7. Iagaru A, Masamed R, Silberman H, Keesara S, Conti PS. The Role of 18F FDG PET/CT and Breast MRI in the Management of Breast Cancer. ASCO Annual Meeting, Atlanta, GA. Jun 2-6, 2006.
8. Iagaru A, Quon A, Ikeda D, Daniel B, Goris ML, McDougall IR, Gambhir SS. 18F FDG PET/CT, Breast MRI and Mammography: Can Breast Cancer Be Reliably Detected? SNM Annual Meeting, San Diego, CA. Jun 3-7, 2006.
9. Iagaru A, Masamed R, Sankhala KK, Chawla S, Menendez L, Fedenko A, Conti PS. Post-Ifosfamide Therapy Inflammation in Musculoskeletal and Soft-Tissue Sarcomas: Evaluation with 18F FDG PET and PET/CT. SNM Annual Meeting, San Diego, CA. Jun 3-7, 2006.
10. Iagaru A, Masamed R, Quan V, Singer PA, Conti PS. Detection of Occult Papillary Thyroid Cancer with 18F FDG PET/CT. SNM Annual Meeting, San Diego, CA. Jun 3-7, 2006.
11. Iagaru A, Quon A, Johnson D, Goris ML, McDougall IR, Gambhir SS. 18F FDG PET/CT in the Management of Melanoma. RSNA Annual Meeting, Chicago, IL. Nov 26 - Dec 1, 2006.
12. Iagaru A, Quon A, Goris ML, Gambhir SS, McDougall IR. 18F FDG PET/CT Evaluation of Osseous and Soft Tissue Sarcomas. RSNA Annual Meeting, Chicago, IL. Nov 26 - Dec 1, 2006.
13. Iagaru A, Quan V, Jadvar H, Conti PS. Sentinel Lymph Node Scintigraphy and 18F FDG PET/CT in the Management of Breast Cancer. ACNP Annual Meeting, San Antonio, Tx. Feb 15-18, 2007.
14. Iagaru A, Wang Y, Mari C, Rodriguez CA, Quon A, Goris ML, Gambhir SS. 18F FDG PET/CT Prediction of Response to Chemotherapy in Lymphoma: When is the Optimal Time for the First Re-Evaluation Scan? ACNP Annual Meeting, San Antonio, Tx. Feb 15-18, 2007.
15. Iagaru A, Mittra E, Kaplan MJ, Quon A, Gambhir SS. 18F FDG PET/CT in Squamous Cell Carcinoma of the Head and Neck: What is the Definition of Whole-Body Scanning? SNM Annual Meeting, Washington, DC. Jun 2-6, 2007.
16. Iagaru A, Mittra E, Quon A, Gambhir SS, McDougall IR. 18F FDG PET/CT Evaluation of Ovarian Cancer. SNM Annual Meeting, Washington, DC. Jun 2-6, 2007.
17. Iagaru A, Zhu H, Mari C, Knox SJ, Goris ML. 90Y-Ibritumomab (Zevalin®) Therapy of Refractory/Relapsed Non-Hodgkin Lymphoma: Clinical Experience. SNM Annual Meeting, Washington, DC. Jun 2-6, 2007.
18. Iagaru A, Zhu H, Mari C, Knox SJ, Ganjoo K, Goris ML. Comparison of Efficacy and Toxicity of Bexxar and Zevalin in the Management of Refractory Non-Hodgkin's Lymphoma. EANM Annual Congress, Copenhagen, Denmark. Oct 13-17, 2007.
19. Iagaru A, McDougall IR. 18F FDG PET/CT in the Management of Papillary Thyroid Cancer, with an Emphasis on Thyroglobulin, TSH and Lesion SUVmax Values. EANM Annual Congress, Copenhagen, Denmark. Oct 13-17, 2007.
20. Iagaru A, Quon A, Jacobs C, Marina N, McDougall IR, Gambhir SS. Osseous and soft tissue sarcomas: when can 18F FDG PET/CT evaluation provide useful information? EANM Annual Congress, Copenhagen, Denmark. Oct 13-17, 2007.
21. Iagaru A, Rodriguez CA, El-Maghraby T, Quon A, Gambhir SS, McDougall IR. 18F FDG PET/CT Evaluation of Patients with Cervical Cancer. RSNA Annual Meeting, Chicago, IL. Nov 25-30, 2007.
22. Iagaru A, Mittra E, Le Q, Quon A, Gambhir SS. 18F FDG PET/CT in Nasopharyngeal Carcinoma: What Do We Need to Scan? RSNA Annual Meeting, Chicago, IL. Nov 25-30, 2007.
23. Iagaru A, Mittra E, Quon A, Daniel B, Ikeda D, Herfkens R, McDougall IR, Gambhir SS. 18F FDG PET/CT Evaluation of Patients with Breast Cancer. RSNA Annual Meeting, Chicago, IL. Nov 25-30, 2007.
24. Iagaru A, Zhu H, Mari C, Knox SJ, Ganjoo K, Goris ML. 131I-Tositumomab (Bexxar®) vs. 90Y-Ibritumomab (Zevalin®) in Refractory/Relapsed Non-Hodgkin's Lymphoma. ACNP Annual Meeting, Newport Beach, CA. Feb 14-17, 2008.
25. Iagaru A, Mittra E, Quon A, Gambhir SS. 18F FDG PET/CT in Head and Neck Cancers: What is the Definition of Whole-Body Scanning? ACNP Annual Meeting, Newport Beach, CA. Feb 14-17, 2008.
26. Iagaru A. Sarcomas: Classification, Diagnosis, and Therapeutic Approaches with an Emphasis on the Role of 18F FDG PET/CT. Northern California Chapter SNM Annual Meeting, Pleasanton, CA. Feb 28, 2008.

27. Iagaru A, Mittra ES, Gambhir SS, Goris ML. Can 111In-Ibritumomab Imaging Predict the Outcome of 90Y-Ibritumomab (Zevalin®) Therapy in Refractory Non-Hodgkin's Lymphoma (NHL)? SNM Annual Meeting, New Orleans, LA. Jun 14-18, 2008.

28. Mittra ES, Quon A, McDougall IR, Gambhir SS, Iagaru A. 18F-FDG PET/CT in the Evaluation of Pediatric Sarcomas. SNM Annual Meeting, New Orleans, LA. Jun 14-18, 2008.

29. Iagaru A, Knox SJ, Goris ML. 131I-Tositumomab (Bexxar®) Therapy of Refractory/Relapsed Non-Hodgkin Lymphoma: Clinical Experience. EANM Annual Congress, Munich, Germany. Oct 11-15, 2008.

30. Iagaru A, Mittra ES, Quon A, Jacobs C, Marina N, Gambhir SS. 18F FDG PET/CT Evaluation of Osseous and Soft Tissue Sarcomas: Differences between Adult and Pediatric Patients. EANM Annual Congress, Munich, Germany. Oct 11-15, 2008.

31. Iagaru A, Mittra ES, Dick DW, Goris ML, Gambhir SS. A Novel Strategy for a Cocktail 18F Fluoride and 18F FDG PET/CT Scan for Evaluation of Malignancy. SNM Annual Meeting, Toronto, Canada. Jun 13-17, 2009.

32. Iagaru A, Gambhir SS. 18F FDG PET/CT Evaluation of Response to Oncolytic Herpes Simplex Virus (NV 1020) Therapy in Patients with Colorectal Cancer Metastatic to the Liver. SNM Annual Meeting, Toronto, Canada. Jun 13-17, 2009.

33. Iagaru A, Knox SJ, Goris ML. 131I-Tositumomab (Bexxar®) vs. 90Y-Ibritumomab (Zevalin®) in Refractory/Relapsed Non-Hodgkin's Lymphoma: Clinical Experience. SNM Annual Meeting, Toronto, Canada. Jun 13-17, 2009.

34. Iagaru A, Mittra ES, Dick, DW, Quon A, Gambhir SS. Prospective Evaluation of 99mTc-MDP Scintigraphy, 18F NaF PET/CT and 18F FDG PET/CT for Detection of Skeletal Metastases. EANM Annual Congress, Barcelona, Spain. Oct 10-14, 2009.

35. Iagaru A, Mittra ES, Dick DW, Goris ML, Gambhir SS. Cocktail 18F Fluoride and 18F FDG PET/CT Scan for Evaluation of Malignancy. EANM Annual Congress, Barcelona, Spain. Oct 10-14, 2009

36. Mittra ES, Quon A, Gambhir SS, Iagaru A. Efficacy of 18F-FDG PET/CT for Breast Cancer. EANM Annual Congress, Barcelona, Spain. Oct 10-14, 2009.

37. Iagaru A, Mittra ES, Dick DW, Goris ML, Gambhir SS. Cocktail 18F Fluoride and 18F FDG PET/CT Scan for Evaluation of Malignancy. WRSNM Annual Meeting, Monterey, CA. Oct 29-Nov 1, 2009.

38. Iagaru A, Young P, Mittra ES, Quon A, Dick DW, Gambhir SS, Herfkens R. Prospective Evaluation of 99mTc-MDP Scintigraphy, 18F NaF PET/CT, 18F FDG PET/CT and Whole-Body MRI for Detection of Skeletal Metastases. RSNA Annual Meeting, Chicago, IL. Nov 29-Dec 4, 2009.

39. Iagaru A, Mittra ES, Dick DW, Goris ML, Gambhir SS. Combined 18F NaF and 18F FDG PET/CT Scan for Evaluation of Malignancy: Beyond the Pilot Study. ACNM/SNM Mid-Winter Meeting, Albuquerque, NM. Jan 27-29, 2010.

40. Iagaru A, Mittra ES, Dick DW, Gambhir SS. Combined 18F NaF and 18F FDG PET/CT Scan for Evaluation of Malignancy: Beyond the Pilot Study. EANM Annual Congress, Vienna, Austria. Oct 9-13, 2010.

41. Iagaru A, Maeda LS, Lin FI, Hoppe RT, Rosenberg SA, Gambhir SS, Advani RH. Classical Hodgkin Lymphoma in First Complete Remission: Is There a Role for 18F FDG PET/CT Surveillance? EANM Annual Congress, Vienna, Austria. Oct 9-13, 2010.

42. Lin IF, Rao JE, Mittra ES, Gambhir SS, Iagaru A. Prospective Comparison of Combined 18F FDG and 18F NaF vs. Conventional 18F FDG PET/CT Imaging for Detection of Malignancy. RSNA Annual Meeting, Chicago, IL. Nov 27-Dec 2, 2010.

43. Iagaru A, Maeda LS, Lin FI, Hoppe RT, Rosenberg SA, Gambhir SS, Advani RH. Classical Hodgkin Lymphoma in First Complete Remission: Is There a Role for 18F FDG PET/CT Surveillance? ACNM/SNM Mid-Winter Meeting, Palm Springs, CA. Jan 20-23, 2011.

44. Nguyen JQ, Davis K, Mittra ES, Quon A, Gambhir SS, Marina N, Iagaru A. Comparison of Clinical Utility of 18F FDG PET/CT and 99mTc MDP Bone Scintigraphy in Patients with Ewing's Sarcoma and Other Forms of Sarcomas. ACNM/SNM Mid-Winter Meeting, Palm Springs, CA. Jan 20-23, 2011.

45. Iagaru A, Mittra ES, Sathekge M, Prakash V, Iyer V, Dick D, Lapa P, Isidoro J, de Lima J, Gambhir SS. Combined 18F NaF and 18F FDG PET/CT: Initial Results of a Multi-Center Trial. SNM Annual Meeting, San Antonio, TX. Jun 4-8, 2011.

46. Iagaru A, Mosci C, Mittra ES, Shen B, Chin F, Chen X, Telli M, Gambhir SS. 18F FPPRGD2 in Breast Cancer Subjects: A Novel PET Radiopharmaceutical for Imaging αvβ3 Integrin Levels. SNM Annual Meeting, San Antonio, TX. Jun 4-8, 2011.

47. Nguyen JQ, Davis K, Mittra ES, Gambhir SS, Marina N, Iagaru A. Clinical Utility of 18F FDG PET/CT and 99mTc MDP Bone Scintigraphy in Patients with Ewings Sarcoma and Other Sarcomas. RSNA Annual Meeting, Chicago, IL. Nov 26-Dec 1, 2011.

48. Takehana C, Twist C, Mittra E, Quon A, Gambhir SS, Iagaru A. Post-Transplant Lymphoproliferative Disorder: Is There a Role for 18F FDG PET/CT? RSNA Annual Meeting, Chicago, IL. Nov 26-Dec 1, 2011.

49. Sampath SC, Sampath SC, Lutz AM, Willmann JK, Mittra ES, Gambhir SS, Iagaru A. The Value of Combined 18F NaF and 18F FDG PET/CT Versus CT Alone for Evaluation of Osseous Malignancy. RSNA Annual Meeting, Chicago, IL. Nov 26-Dec 1, 2011.

50. Mosci C, Akatsu H, Basina M, Dosiou C, Iagaru A. The role of diagnostic 123I whole body scan prior to ablation of thyroid remnant in patients with papillary thyroid cancer. SNM Annual Meeting, Miami, FL. Jun 9-13, 2012.

51. Davidzon G, Wakelee H, Neal J, Mittra ES, Quon A, Iagaru A. Utility of 18F FDG PET/CT in patients with advanced thymic neoplasms. SNM Annual Meeting, Miami, FL. Jun 9-13, 2012.

52. Sampath SC, Sampath SC, Lutz A, Willmann JK, Mittra ES, Gambhir SS, Iagaru A. Evaluation of NaF PET/CT, FDG PET/CT, combined NaF/FDG PET/CT and CT alone for detection of bone metastases. SNM Annual Meeting, Miami, FL. Jun 9-13, 2012.

53. Takehana C, Mittra ES, Quon A, Gambhir SS, Iagaru A. 18F FDG PET/CT in the management of patients with post-transplant lymphoproliferative disorder. SNM Annual Meeting, Miami, FL. Jun 9-13, 2012.

54. Iagaru A, Mosci C, Mittra ES, Shen B, Chin F, Fischbein N, Gambhir SS. 18F FPPRGD2 in GBM: Imaging αvβ3 integrin levels as a biomarker of disease recurrence. SNM Annual Meeting, Miami, FL. Jun 9-13, 2012.

55. Keu KV, Mittra ES, Quon A, Iagaru A. Metabolic Imaging Patterns of Complete Local Response to Chemoradiation in Patients with Nasopharyngeal Carcinoma: A Review. EANM Annual Congress, Milan, Italy. Oct 27-31, 2012.

56. Keu KV, Nair VS, Mittra ES, Quon A, Gambhir SS, Iagaru A. The Impact of Partial Volume Correction in the Evaluation of Solitary Pulmonary Nodules by FDG PET/CT in a Population at Intermediate Risk of Lung Cancer. EANM Annual Congress, Milan, Italy. Oct 27-31, 2012.

57. Keu KV, Mittra ES, Quon A, Gambhir SS, Iagaru A. Feasibility of Limited Thoracic FDG PET/CT for the Evaluation of Solitary Pulmonary Nodules in Patients With Intermediate and High Risk of Lung Cancer. EANM Annual Congress, Milan, Italy. Oct 27-31, 2012.

58. Iagaru A, Mosci C, Mittra ES, Shin B, Chin F, Gambhir SS. αvβ3 Integrins as a Biomarker of Disease Recurrence in Glioblastoma Multiforme: Initial Clinical Results Using 18F FPPRGD2 PET/CT. EANM Annual Congress, Milan, Italy. Oct 27-31, 2012.

59. Iagaru A, Mosci C, Akatsu H, Basina M, Dosiou C, I. Ross McDougall. Post-Surgical 131I Ablation in Patients with Papillary Thyroid Cancer: The Role of Diagnostic 123I Whole Body Scan. EANM Annual Congress, Milan, Italy. Oct 27-31, 2012.

60. Davidzon G, Mosci C, Mittra ES, Shin B, Chin F, Gambhir SS, Iagaru A. Biodistribution and Kinetics of 18F FPPRGD2 PET/CT in the Evaluation of Suspected Recurrence in Glioblastoma Multiforme. ACNM/SNMMI Mid-Winter Meeting, New Orleans, LA. Jan 24-27, 2013.

61. Keu KV, Mittra E, Quon A, Iagaru A. Pre-Treatment 18F FDG PET/CT Findings Can Not Predict Late Recurrence of Nasopharyngeal Carcinoma. SNMMI Annual Meeting, Vancouver, BC. Jun 8-12, 2013.

62. Keu KV, Mittra E, Quon A, Iagaru A. The Value of Post-Therapy 18F FDG PET/CT Surveillance Scans in the Detection of Recurrent Nasopharyngeal Carcinoma. SNMMI Annual Meeting, Vancouver, BC. Jun 8-12, 2013.

63. Mosci C, Akatsu H, Basina M, Dosiou C, McDougall IR, Iagaru A. Implications of 123I Whole Body Scan Pre-Ablation of Thyroid Remnant in Papillary Thyroid Cancer Patients. SNMMI Annual Meeting, Vancouver, BC. Jun 8-12, 2013.

64. Mosci C, Ganjoo K, Norton J, Mittra E, Quon A, Iagaru A. The Value of 18F FDG PET/CT in the Evaluation of Soft Tissue Sarcomas. SNMMI Annual Meeting, Vancouver, BC. Jun 8-12, 2013.

65. Mosci C, Marina N, Ganjoo K, Mohler D, Avedian R, Mittra E, Quon A, Iagaru A. 18F FDG PET/CT and Dedicated CT in the Evaluation of Bone Sarcomas. SNMMI Annual Meeting, Vancouver, BC. Jun 8-12, 2013.

66. Mosci C, Marina N, Mittra E, Quon A, Iagaru A. 18F FDG PET/CT Evaluation of Pediatric Sarcomas. SNMMI Annual Meeting, Vancouver, BC. Jun 8-12, 2013.

67. Davidzon G, Mosci C, Mittra E, Shen B, Chin F, Gambhir SS, Iagaru A. Biodistribution and Kinetics of 18F FPPRGD2 in Cancer Patients. SNMMI Annual Meeting, Vancouver, BC. Jun 8-12, 2013.

68. Hope T, Keu KV, Robb F, Herfkens R, Iagaru A. Effect of Anterior Body MRI Coils on PET Acquisitions and Evaluation of a Novel Minimally Attenuating PET/MR Coil. SNMMI Annual Meeting, Vancouver, BC. Jun 8-12, 2013.

69. Iagaru A, Davidzon G, Mosci C, Shen B, Chin FT, Gambhir SS. Pilot Prospective Evaluation of the Novel PET/CT Radiopharmaceutical 18F FPPRGD2 in Patients with Non-Small Cell Lung Cancer. WMIS Annual Congress, Savannah, GA. Sep 18-21, 2013.

70. Iagaru A, Davidzon G, Mosci C, Kumar M, Shen B, Chin FT, Gambhir SS. Pilot Prospective Evaluation of Early Response to Bevacizumab Treatment Using the Novel PET/CT Radiopharmaceutical 18F FPPRGD2. EANM Annual Congress, Lyon, France. Oct 19-23, 2013.

71. Keu KV, Lutchman G, Quon A, Mittra ES, Iagaru A. The Role of 99mTc-MDP Bone Scintigraphy in the Workup of Patients with Hepatocellular Carcinoma. RSNA Annual Meeting, Chicago, IL. Dec 1-6, 2013.

72. Keu KV, Twist C, Quon A, Mittra ES, Iagaru A. Semi-quantitative Evaluation of Neuroblastoma Tumor Burden Using 123I mIBG and 18F FDG PET/CT. RSNA Annual Meeting, Chicago, IL. Dec 1-6, 2013.

73. Jackson T, Mosci C, von Eyben R, Mittra ES, Ganjoo K, Biswal S, Gambhir SS, Iagaru A. Combined 18F NaF and 18F FDG PET/CT in the Evaluation of Sarcoma Patients. ACNM/SNMMI Mid-Winter Meeting, Palm Springs, CA. Feb 6-9, 2014.

74. Iagaru A, Mosci C, Jamali M, Minamimoto R, Mittra ES, Shin B, Chin F, Gambhir SS. $^{18}$F FPPRGD2 PET/CT Evaluation of Patients With Suspected Recurrence Of Glioblastoma Multiforme. SNMMI Annual Meeting, St Louis, MO. Jun 7-11, 2014.

75. Iagaru A, Mittra ES, Zaharchuk G, Prost RW, Elekes A, Anderson J, Bobb C, Lahrman J, Gold GE, Gambhir SS. $^{18}$F FDG SUVmax Values in Normal Tissues and Malignant Lesions from the First Time-of-Flight Whole-Body PET/MRI Scanner: Comparison with Values from PET/CT. SNMMI Annual Meeting, St Louis, MO. Jun 7-11, 2014.

76. Castaneda P, Leonard Z, Wen M, Kwofie J, Mittra ES, Iagaru A. Initial Experience with $^{223}$Ra Vial Delivery (Alpharadin®) vs. Unit-Dose Delivery (Xofigo®). SNMMI Annual Meeting, St Louis, MO. Jun 7-11, 2014.

77. Iagaru A, Mosci C, Jamali M, Loening A, Mittra ES, Gambhir SS, Vasanawala SS. Prospective Evaluation of Combined 18F NaF/18F FDG PET/CT vs. Whole-Body MRI in Patients with Breast and Prostate Cancer. SNMMI Annual Meeting, St Louis, MO. Jun 7-11, 2014.

78. Iagaru A, Mosci C, Jamali M, Loening A, Mittra ES, Gambhir SS, Vasanawala SS. Prospective Evaluation of Combined 18F NaF/18F FDG PET/CT vs. Whole-Body MRI in Patients with Breast and Prostate Cancer. WFNMB Congress, Cancun, Mexico. Aug 27-31, 2014.

79. Iagaru A, Jamali M, Minamimoto R, Mittra ES, Gold GE, Vasanawala S, Gambhir SS, Zaharchuk G. First evaluation of a time-of-flight whole-body PET/MRI scanner in oncology patients: comparison with PET/CT. WFNMB Congress, Cancun, Mexico. Aug 27-31, 2014.

80. Iagaru A, Mosci C, Keu KV, Mittra ES, Hancock S, Pachynski R, Srinivas S, Gambhir SS 18F NaF and 18F FDG PET/CT for Evaluation of Prostate Cancer Patients. WMIS Annual Congress, Seoul, Korea. Sep 17-20, 2014.

81. Iagaru A, Jamali M, Minamimoto R, Mittra ES, Gold GE, Vasanwala S, Gambhir SS, Zaharchuk G. First evaluation of a time-of-flight whole-body PET/MRI scanner in oncology patients: comparison with PET/CT. EANM Annual Congress, Stockholm, Sweden. Oct 18-22, 2014.

82. Iagaru A, Mosci C, Jamali M, Barkhodari A, Minamimoto R, Loening A, Mittra ES, Gambhir SS, Vasanawala SS. Prospective Evaluation of Combined 18F NaF/18F FDG PET/CT vs. Whole-Body MRI in Patients with Breast and Prostate Cancer. WRSNM Annual Meeting, Seattle, WA. Oct 30 - Nov 2, 2014.

83. Sabbah N, Jackson T, Mosci C, Jemali M, Minamimoto R, Quon A, Iagaru A. Characterization of 18F-NaF Uptake in Normal Bone, Bone Metastases, Degenerative Changes and Extra-Skeletal Tissues: An Atlas of Standardized Uptake Values. RSNA Annual Meeting, Chicago, IL. Nov 30 - Dec 5, 2014.

84. Minamimoto R, Iagaru A, Jamali M, Holley D, Vasanawala S, Herfkens, R Sawyer AM, Glover G, Gambhir SS, Zaharchuk G. Whole-body Simultaneous Time-of-Flight PET-MRI: Initial Clinical Experience. RSNA Annual Meeting, Chicago, IL. Nov 30 - Dec 5, 2014.

85. Thompson H, Jamali M, Minamimoto R, Barkhodari A, Quon A, Mittra ES, Iagaru A. SUV Values in Cancer Lesions: A Prospective, Matched Comparison of Data from Non-TOF vs. TOF PET/CT Scanners. ACNM/SNMMI Mid-Winter Meeting, San Antonio, TX. Jan 22-25, 2015.

86. Minamimoto R, Levin CS, Jamali M, Barkhodari A, Holley D, Zaharchuk G, Iagaru A. The potential of TOF PET-MRI for reducing artifacts in PET images. 4th Conference on PET/MR and SPECT/MR, Isola d'Elba, Italy. May 17-21, 2015.

87. Iagaru A, Minamimoto R, Jamali M, Barkhodari A, Gambhir SS, Vasanawala SS. Imaging Patients with Breast and Prostate Cancers Using Combined 18F NaF/18F FDG and TOF simultaneous PET/ MRI. 4th Conference on PET/MR and SPECT/MR, Isola d'Elba, Italy. May 17-21, 2015.

88. Iagaru A, Minamimoto R, Mosci C, Jamali M, Barkhodari A, Loening AM, Taviani V, Mittra E, Gambhir SS, Vasanawala S. Prospective evaluation of 99mTc MDP scintigraphy, 18F NaF/18F FDG PET/CT and WBMRI in patients with breast and prostate cancers. SNMMI Annual Meeting, Baltimore, MD. Jun 6-10, 2015.

89. Iagaru A, Minamimoto R, Jamali M, Barkhodari A, Obara P, Loening AM, Taviani V, Mittra E, Gambhir SS, Vasanawala S. Imaging patients with breast and prostate cancers using combined 18F NaF/18F FDG and TOF simultaneous PET/MRI. SNMMI Annual Meeting, Baltimore, MD. Jun 6-10, 2015.

90. Lantos J, Mittra E, Levin CS, Iagaru A. Standard OSEM vs. regularized PET image reconstruction: qualitative and semi-quantitative comparison. SNMMI Annual Meeting, Baltimore, MD. Jun 6-10, 2015.

91. Minamimoto R, Jamali M, Barkhodari A, Mosci C, Mittra E, Shen B, Chin F, Gambhir SS, Iagaru A. 18F-FPPRGD2 PET as a Surrogate Biomarker of Integrin αvβ3 Expression Before and After Anti-angiogenesis Treatment. SNMMI Annual Meeting, Baltimore, MD. Jun 6-10, 2015.

92. Iagaru A, Minamimoto R, Jamali M, Barkhodari A, Gambhir SS, Vasanawala SS. Combined 18F NaF/18F FDG and TOF simultaneous PET/ MRI in patients with breast and prostate cancer. WMIS Annual Congress, Honolulu, HI. Sep 2-5, 2015.

93. Xu G, Minamimoto R, Quon A, Mittra E, Iagaru A. Semi-quantitative assessment of 18F FDG uptake in the normal skeleton using simultaneous PET/MRI: initial comparison to PET/CT in 50 patients. EANM Annual Congress, Hamburg, Germany. Oct 10-14, 2015.

94. Minamimoto R, Jamali M, Barkhodari A, Holley D, Zaharchuk G, Levin C, Iagaru A. Improvements in PET Image quality from TOF PET/MRI. EANM Annual Congress, Hamburg, Germany. Oct 10-14, 2015.

95. Iagaru A, Lantos J, Mittra EM, Levin C. Standard OSEM vs. Regularized PET Image Reconstruction: Qualitative and Semi-Quantitative Comparison. EANM Annual Congress, Hamburg, Germany. Oct 10-14, 2015.

96. Minamimoto R, Loening A, Obara P, Taviani V, Gambhir SS, Vasanawala S, Iagaru A. Combined 18F NaF/18F FDG and TOF simultaneous PET/ MRI: One-Stop Shop Staging of Patients with Breast and Prostate Cancers. EANM Annual Congress, Hamburg, Germany. Oct 10-14, 2015.

97. Iagaru A, Minamimoto R, Schneider B, Chin FT, Mittra ES, Taviani V, Vasanawala S, Mueller A, Berndt M, Stephens A, Gambhir SS. Pilot Prospective Evaluation of 68Ga-DOTA-Bombesin (68Ga-RM2 or 68Ga-Bombesin) with TOF PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer. WRSNM Annual Meeting, Monterey, CA. Oct 22-25, 2015.

98. Minamimoto R, Loening AM, Taviani V, Gambhir SS, Vasanawala SS, Iagaru A. Imaging Patients with Breast and Prostate Cancers Using Combined 18F NaF/18F FDG and TOF simultaneous PET/ MRI. RSNA Annual Meeting, Chicago, IL. Nov 29 - Dec 5, 2015.

99. Iagaru A, Minamimoto R, Hancock S, Mittra ES, Loening A, Vasanawala S, Gambhir SS. 68Ga-DOTA-Bombesin (68Ga-RM2 or 68Ga-Bombesin) PET vs. 68Ga-PSMA PET: A Pilot Prospective Evaluation in Patients with Biochemical Recurrence of Prostate Cancer. ASCU GU Symposium, San Francisco, CA. Jan 7-9, 2016.

100. Iagaru A, Minamimoto R, Loening A, Mueller A, Berndt M, Stephens A, Vasanawala S. Biochemically Recurrent Prostate Cancer: 68Ga-DOTA-Bombesin (68Ga -RM2 or 68Ga -Bombesin) PET/MRI Is Superior to Conventional Imaging. ACNM/SNMMI Mid-Winter Meeting, Orlando, FL. Jan 28-31, 2016

101. Iagaru A, Minamimoto R, Loening A, Vasanawala S, Gambhir SS. 68Ga-DOTA-Bombesin (68Ga-RM2 or 68Ga-Bombesin) PET vs. 68Ga-PSMA PET: A Pilot Prospective Evaluation in Patients with Biochemical Recurrence of Prostate Cancer. ACNM/SNMMI Mid-Winter Meeting, Orlando, FL. Jan 28-31, 2016.

102. Wu F, Jamali M, Hatami N, Sonni I, Baratto L, Guo HH, Quon A, Mittra E, Iagaru A. 99mTc-MDP scintigraphy vs. 18F-NaF PET/CT for detection of skeletal metastases. SNMMI Annual Meeting, San Diego, CA. Jun 11-15, 2016.

103. Iagaru A, Minamimoto R, Loening A, Mueller A, Berndt M, Stephens A, Vasanawala S. Biochemically recurrent prostate cancer: 68Ga-RM2 (formerly known as 68Ga-Bombesin or BAY86-7548) PET/MRI is superior to conventional imaging. SNMMI Annual Meeting, San Diego, CA. Jun 11-15, 2016.

104. Deller T, Khalighi MM, Lantos J, Gulaka P, Iagaru A. Evaluation of improved scatter correction with highly targeted 68Ga-labeled radiopharmaceuticals. SNMMI Annual Meeting, San Diego, CA. Jun 11-15, 2016.

105. Iagaru A, Sonni I, Minamimoto R, Loening A, Vasanawala S. 68Ga-RM2 PET/MRI Evaluation of Gastrin-Releasing Peptide Receptors Status in Biochemically Recurrent Prostate Cancer. EANM Annual Congress, Barcelona, Spain. Oct 15-19, 2016.

106. 18F NaF/18F FDG simultaneous PET/ MRI with TOF in patients with breast and prostate cancers. Sonni I, Minamimoto R, Loening AM, Taviani V, Gambhir SS, Vasanawala SS, Iagaru A. EANM Annual Congress, Barcelona, Spain. Oct 15-19, 2016.

107. Sonni I, Minamimoto R, Loening A, Vasanawala S, Iagaru A. 68Ga-RM2 PET/MRI in biochemically recurrent prostate cancer: a comparison with conventional imaging. RSNA Annual Meeting, Chicago, IL. Nov 27 - Dec 3, 2016.

108. Harrison C, Sonni I, Loening A, Vasanawala S, Iagaru A. 68Ga-RM2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer and Negative Conventional Imaging. ACNM/SNMMI Mid-Winter Meeting, Phoenix, AR. Jan 18-22, 2017.

109. Sonni I, Park S, Baratto L, Hatami N, Davidzon G, Srinivas S, Gambhir SS, Iagaru A. Initial Experience with a SiPM-based PET/CT Scanner: Influence of Acquisition Time on Image Quality. SNMMI Annual Meeting, Denver, CO. Jun 10-14, 2017.

110. Zacharias C, Harrison C, Ghanouni P, Sonn G, Iagaru A. 68Ga PSMA-11 PET/MRI in Patients with Newly Diagnosed Intermediate and High-Risk Prostate Cancers. SNMMI Annual Meeting, Denver, CO. Jun 10-14, 2017.

111. Park S, Baratto L, Hatami N, Davidzon G, Srinivas S, Gambhir SS, Iagaru A. Initial Experience with a New PET/CT System Using SiPM Detectors: Image Quality Comparison with Standard PET/CT. SNMMI Annual Meeting, Denver, CO. Jun 10-14, 2017.

112. Harrison C, Sonni I, Loening A, Vasanawala S, Iagaru A. Detection of Recurrent Prostate Cancer Using 68Ga-RM2 PET/MRI in Patients with Negative Conventional Imaging. SNMMI Annual Meeting, Denver, CO. Jun 10-14, 2017.

113. Sonni I, Minamimoto R, Taviani V, Hatami N, Gambhir SS, Vasanawala S, Iagaru A. Imaging Patients with Breast and Prostate Cancers Using Combined 18F NaF/18F FDG and TOF simultaneous PET/ MRI. SNMMI Annual Meeting, Denver, CO. Jun 10-14, 2017.

114. Gandhi H, Holley D, Gulaka P, Iagaru A. 68Ga PSMA-11 PET/MRI: Influence of Acquisition Time on Image Quality. SNMMI Annual Meeting, Denver, CO. Jun 10-14, 2017

115. Baratto L, Park S, Hatami N, Davidzon G, Srinivas S, Gambhir SS, Iagaru A. SiPM PET/CT vs. Standard PET/CT: A Pilot Study Comparing Semi-Quantitative Measurements in Normal Tissues and Lesions. SNMMI Annual Meeting, Denver, CO. Jun 10-14, 2017.

116. Park S, Baratto L, Gulaka P, Herfkens R, Witteles R, Iagaru A. Florbetaben Whole-Body PET/MRI for Evaluation of Systemic Amyloid Deposition. EANM Annual Congress, Vienna, Austria. Oct 21-25, 2017.

117. Park S, Zacharias C, Harrison C, Baratto L, Hatami N, Iagaru A. 68Ga-PSMA-11 PET/MRI in Primary Intermediate / High-Risk Prostate Cancer. EANM Annual Congress, Vienna, Austria. Oct 21-25, 2017.

118. Park S, Baratto L, Gandhi H, Gulaka P, Iagaru A. 68Ga-PSMA-11 PET/MRI: Influence of Scan Time on Image Quality. EANM Annual Congress, Vienna, Austria. Oct 21-25, 2017.

119. Sonni I, Park S, Baratto L, Hatami N, Davidzon G, Srinivas S, Gambhir SS, Iagaru A. First Experience with Fast Imaging Using Discovery MI PET/CT. EANM Annual Congress, Vienna, Austria. Oct 21-25, 2017.

120. Park S, Baratto L, Hatami N, Davidzon G, Srinivas S, Nair V, Iagaru A. Improved Pulmonary Nodule Detection Using a Next Generation 18F-FDG PET Imaging System. EANM Annual Congress, Vienna, Austria. Oct 21-25, 2017.

121. Park S, Baratto L, Hatami N, Davidzon G, Srinivas S, Gambhir SS, Iagaru A. Initial Experience with a New PET/CT System Using SiPM Detectors. EANM Annual Congress, Vienna, Austria. Oct 21-25, 2017.

122. Baratto L, Park S, Hatami N, Davidzon G, Srinivas S, Gambhir SS, Iagaru A. SiPM PET/CT vs. Standard PET/CT: A Pilot Study Comparing Semi-Quantitative Measurements in Normal Tissues and Lesions. EANM Annual Congress, Vienna, Austria. Oct 21-25, 2017.

123. Park S, Zacharias C, Harrison C, Baratto L, Hatami N, Iagaru A. 68Ga-PSMA PET/MRI in Primary Intermediate / High-Risk Prostate Cancer. RSNA Annual Meeting, Chicago, IL. Nov 26 - Dec 1, 2017.

124. Park S, Baratto L, Hatami N, Davidzon G, Srinivas S, Nair V, Iagaru A. Improved Pulmonary Nodule Detection Using a Next Generation 18F-FDG PET Imaging System. RSNA Annual Meeting, Chicago, IL. Nov 26 - Dec 1, 2017.

125. Park S, Baratto L, Hatami N, Davidzon G, Srinivas S, Gambhir SS, Iagaru A. Initial Experience with a New PET/CT System Using SiPM Detectors. RSNA Annual Meeting, Chicago, IL. Nov 26 - Dec 1, 2017.

126. Baratto L, Park S, Hatami N, Davidzon G, Srinivas S, Gambhir SS, Iagaru A. SiPM PET/CT vs. Standard PET/CT: A Pilot Study Comparing Semi-Quantitative Measurements in Normal Tissues and Lesions. RSNA Annual Meeting, Chicago, IL. Nov 26 - Dec 1, 2017.

127. Moradi F, Iagaru A. Diagnostic Performance Of 68Ga-DOTATATE PET/CT in Evaluation of Neuroendocrine Malignancies: What Parameters Are Useful? RSNA Annual Meeting, Chicago, IL. Nov 26 - Dec 1, 2017.

128. Song H, Harrison C, Tu P, Yohannan TK, Davidzon G, Iagaru A. 18F FDG PET/CT Evaluation of Patients with Breast Cancer. ACNM/SNMMI Mid-Winter Meeting, Orlando, FL. Jan 25-27, 2018.

129. Park S, Hatami N, Baratto L, Yohannan T, Davidzon G, Iagaru A. Dual-Time 68Ga-PSMA-11 Imaging for Biochemically Recurrent Prostate Cancer Using LYSO and SiPM-Based Detectors PET/CT. ACNM/SNMMI Mid-Winter Meeting, Orlando, FL. Jan 25-27, 2018.

130. Duan H, Khalaf MH, Baratto L, Sze DY, Srinivas S, Iagaru A. High Quality Imaging and Dosimetry of Yttrium-90 (90Y) Radioembolization Using a SiPM-Based PET/CT scanner. SNMMI Annual Meeting, Philadelphia, PA. Jun 23-26, 2018.

131. Baratto L, Toriihara A, Hatami N, Davidzon G, Srinivas SS, Gambhir SS, Iagaru A. SiPM-based vs LYSO-based 68Ga-DOTA-TATE PET/CT: Comparison of Semi-Quantitative Measurements in Normal Tissues and Lesions. SNMMI Annual Meeting, Philadelphia, PA. Jun 23-26, 2018.

132. Baratto L, Duan H, Gandhi H, Kalighi M, Gulaka P, Iagaru A. The effect of various beta values on image quality and semi-quantitative measurements in 68Ga-labeled GRPR and PSMA PET/MRI images reconstructed with a block sequential regularized expectation maximization algorithm. SNMMI Annual Meeting, Philadelphia, PA. Jun 23-26, 2018.

133. Toriihara A, Baratto L, Nobashi T, Park S, Hatami N, Davidzon G, Kunz P, Iagaru A. Prognostic value of volumetric parameters calculated from 68Ga-DOTA TATE PET/CT in patients with well-differentiated neuroendocrine tumors. SNMMI Annual Meeting, Philadelphia, PA. Jun 23-26, 2018.

134. Toriihara A, Duan H, Park S, Hatami N, Baratto L, Fan A, Iagaru A. 18F-FPPRGD2 PET/CT in patients with metastatic renal cell cancer. SNMMI Annual Meeting, Philadelphia, PA. Jun 23-26, 2018.

135. Baratto L, Harrison C, Davidzon G, Yohannan T, Iagaru A. 68Ga-RM2 PET/MRI Detection of Recurrent Prostate Cancer in Patients with Negative Conventional Imaging. SNMMI Annual Meeting, Philadelphia, PA. Jun 23-26, 2018.

136. Song H, Yohannan T, Srinivas S, Vasanawala S, Iagaru A. Combined "One Stop Shop" NaF/FDG PET/MRI Evaluation of Response to Xofigo® in mCRPC Patients. SNMMI Annual Meeting, Philadelphia, PA. Jun 23-26, 2018.

137. Barrato L, Duan H, Mari C, Davidzon G, Iagaru A. 68Ga-RM2 + 68Ga-PSMA-11 PET: Prospective Evaluation in Patients with Biochemical Recurrence of Prostate Cancer. WMIS Annual Congress, Seattle, WA. Sep 12-15, 2018.

138. Baratto L, Duan H, Harrison C, Mari C, Davidzon G, Yohannan T, Iagaru A. 68Ga-RM2 PET/MRI Detection of Recurrent Prostate Cancer in Patients with Negative Conventional Imaging. EANM Annual Congress, Dusseldorf, Germany. Oct 13-17, 2018.

139. Barrato L, Duan H, Minamimoto R, Mari C, Yohannan T, Davidzon G, Iagaru A. 68Ga-RM2 PET vs. 68Ga-PSMA-11 PET: Prospective Comparison in Patients with Biochemical Recurrence of Prostate Cancer. EANM Annual Congress, Dusseldorf, Germany. Oct 13-17, 2018.

140. Barrato L, Duan H, Hatami N, Yohannan T, Mari C, Davidzon G, Iagaru A. Dual-Time 68Ga-RM2 Imaging for Staging Patients with Newly Diagnosed Intermediate or High-Risk Prostate Cancer Using PMT and SiPM-Based Detectors PET/CT. EANM Annual Congress, Dusseldorf, Germany. Oct 13-17, 2018.

141. Baratto L, Duan H, Gandhi H, Kalighi M, Gulaka P, Iagaru A. The effect of various beta values on image quality and semi-quantitative measurements in 68Ga-labeled GRPR and PSMA PET/MRI images reconstructed with a block sequential regularized expectation maximization algorithm. RSNA Annual Meeting, Chicago, IL. Nov 25-30, 2018.

142. Baratto L, Duan H, Torihara A, Hatami N, Parker S, Nobashi T, Iagaru A. Standardized uptake value atlas: physiological and abnormal 68Ga-RM2 uptake in patients with prostate cancer. RSNA Annual Meeting, Chicago, IL. Nov 25-30, 2018.

143. Baratto L, Harrison C, Davidzon G, Yohannan T, Iagaru A. 68Ga-RM2 PET/MRI Detection of Recurrent Prostate Cancer in Patients with Negative Conventional Imaging. RSNA Annual Meeting, Chicago, IL. Nov 25-30, 2018.

144. Toriihara A, Nobashi T, Baratto L, Park S, Hatami N, Duan H, Mari C, Davidzon G, Yohannan T, Iagaru A. Inter-Reader and Inter-Criteria Agreement for Evaluation of 68Ga-PSMA PET. RSNA Annual Meeting, Chicago, IL. Nov 25-30, 2018.

145. Duan H, Khalaf M, Baratto L, Srinivas S, Sze D, Iagaru A. High Quality Imaging and Dosimetry of Yttrium-90 (90Y) Radioembolization Using a SiPM-Based PET/CT scanner. RSNA Annual Meeting. Chicago, IL. Nov 25-30, 2018.

146. Duan H, Park S, Baratto L, Hatami N, Khalaf HM, Yohannan T, Davidzon G, Iagaru A. Dual-Time 68Ga-PSMA-11 Imaging for Biochemically Recurrent Prostate Cancer Using LYSO and SiPM-Based Detectors PET/CT. RSNA Annual Meeting. Chicago, IL. Nov 25-30, 2018.

147. Baratto L, Toriihara A, Hatami N, Davidzon G, Srinivas SS, Gambhir SS, Iagaru A. SiPM-Based versus LYSO-based 68Ga-DOTA-TATE PET/CT: Comparison of Semi-Quantitative Measurements in Normal Tissues and Lesions. RSNA Annual Meeting. Chicago, IL. Nov 25-30, 2018.

148. Harrison C, Song H, Mari Aparici C, Davidzon G, Iagaru A. Initial Clinical Experience Using 18F-Fluciclovine PET/CT at an Academic Center: Positivity Rate and Correlation with PSA levels. ACNM/SNMMI Mid-Winter Meeting, Palm Springs, CA. Jan 17-19, 2019.

149. Song H, Harrison C, Davidzon G, Mari Aparici C, Iagaru A. Academic Center Comparison of 18F-Fluciclovine PET/CT and Other Imaging Modalities in Biochemically Recurrent Prostate Cancer. ACNM/SNMMI Mid-Winter Meeting, Palm Springs, CA. Jan 17-19, 2019.

150. Harrison C, Song H, Duan H, Davidzon G, Iagaru A. Prospective evaluation of 18F- DCFPyL in Patients with Biochemically Recurrent Prostate Cancer. AUA Annual Meeting, Chicago, IL. May 3-6, 2019.

151. Song H, Harrison C, Guja K, Franc B, Moradi F, Davidzon G, Mari Aparici C, Iagaru A. Prospective evaluation of 18F-DCFPyL and Conventional Imaging in Patients with Biochemically Recurrent Prostate Cancer. SNMMI Annual Meeting, Anaheim, CA. Jun 22-25, 2019.

152. Baratto L, Duan H, Hatami N, Toriihara A, Song H, Iagaru A. Prospective evaluation of 68Ga-RM2 PET/MRI and 68Ga-PSMA11 PET/CT in patients with biochemical recurrence of prostate cancer. SNMMI Annual Meeting, Anaheim, CA. Jun 22-25, 2019.

153. Moradi F, Guja K, Mari Aparici C, Iagaru A. Quantification of uptake in 68Ga-DOTATATE PET: Correlation between standardized uptake values and patient factors. SNMMI Annual Meeting, Anaheim, CA. Jun 22-25, 2019.

154. Toriihara A, Nobashi T, Barratto L, Park S, Hatami N, Duan H, Mari Aparici C, Davidzon G, Iagaru A. Comparison of three interpretation criteria of 68Ga-PSMA PET based on inter- and intra-reader agreement. SNMMI Annual Meeting, Anaheim, CA. Jun 22-25, 2019.

155. Duan H, Song H, Baratto L, Khalaf M, Hatami N, Franc B, Moradi F, Davidzon G, Mari Aparici C, Iagaru A. Prospective Comparison of 18F-DCFPyL PET/CT with 18F-NaF PET/CT for Detection of Skeletal Metastases in Biochemically Recurrent Prostate Cancer. SNMMI Annual Meeting, Anaheim, CA. Jun 22-25, 2019.

156. Duan H, Khalaf M, Baratto L, Srinivas S, Sze D, Iagaru A. Clinical Follow-Up after Imaging and Dosimetry for Yttrium-90 (90Y) Liver Radioembolization Using a SiPM-Based PET/CT Scanner. SNMMI Annual Meeting, Anaheim, CA. Jun 22-25, 2019.

157. Harrison C, Song H, Franc B, Guja K, Moradi F, Davidzon G, Mari Aparici C, Iagaru A. Prospective evaluation of 18F-DCFPyL in Patients with Biochemically Recurrent Prostate Cancer: Positivity Rate and Correlation with PSA levels. SNMMI Annual Meeting, Anaheim, CA. Jun 22-25, 2019.

158. Baratto L, Duan H, Harrrison C, Hatami N, Mai Aparici C, Davidzon G, Yohannan T, Iagaru A. Preliminary Results of a Prospective Study of 68Ga-RM2 PET/MRI for Detection of Recurrent Prostate Cancer in Patients with Negative Conventional Imaging. SNMMI Annual Meeting, Anaheim, CA. Jun 22-25, 2019.

159. Song H, Kunz PL, Franc B, Moradi F, Davidzon G, Iagaru A, Mari Aparici C. Comparison of 68Ga-DOTA-TATE PET/CT for assessment of response to peptide receptor radionuclide therapy after 2 and 4 cycles of Lutathera®: preliminary single academic center experience. NANETS Multidisciplinary NET Medical Symposium, Boston, MA. Oct 3-5, 2019.

160. Barrato L, Duan H, Davidzon G, Iagaru A. 68Ga-RM2 PET Imaging for Staging Patients with Newly Diagnosed Intermediate or High-Risk Prostate Cancer. EANM Annual Congress, Barcelona, Spain. Oct 12-16, 2019.

161. Duan H, Song H, Harrison C, Guja K, Franc B, Moradi F, Mari Aparici C, Davidzon G, Iagaru A. Prospective evaluation of 18F-DCFPyL in Patients with Biochemically Recurrent Prostate Cancer. EANM Annual Congress, Barcelona, Spain. Oct 12-16, 2019.

162. Davidzon G, Lee J, Yang H, Song H, Harrison C, Iagaru A. Machine Learning to Detect Prostate Cancer Recurrence using 18F-Fluciclovine PET. EANM Annual Congress, Barcelona, Spain. Oct 12-16, 2019.

163. Duan H, Khalaf MH, Baratto L, Srinivas S, Sze DY, Iagaru A. Clinical Follow-Up after Imaging and Dosimetry for Yttrium-90 (90Y) Liver Radioembolization Using a SiPM-Based PET/CT Scanner. RSNA Annual Meeting, Chicago, IL. Dec 1-6, 2019.

164. Baratto L, Duan H, Harrison C, Mari C, Davidzon G, Moradi F, Iagaru A. Interim Analysis Results of a Prospective Study of 68Ga-RM2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer and Negative Conventional Imaging. RSNA Annual Meeting, Chicago, IL. Dec 1-6, 2019.

165. Duan H, Song,H, Baratto L, Hatami N, Franc BL, Moradi F, Davidzon G, Mari Aparici C, Iagaru A. Prospective Comparison of 18F-DCFPyL PET/CT with 18F-NaF PET/CT for Detection of Skeletal Metastases in Biochemically Recurrent Prostate Cancer. RSNA Annual Meeting, Chicago, IL. Dec 1-6, 2019.

166. Hong S, Harrison C, Guja KE, Franc BL, Moradi F, Davidzon H, Mari Aparici C, Iagaru A. Comparison of 18F-Fluciclovine PET/CT with Conventional Imaging in Prostate Cancer Patients with Biochemical Recurrence. RSNA Annual Meeting, Chicago, IL. Dec 1-6, 2019.

167. Baratto L, Song H, Duan H, Mari Aparici C, Hatami N, Davidzon G, Moradi F, Iagaru A. Interim Analysis Results of a Prospective Study of 68Ga-RM2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer and Negative Conventional Imaging. AUA Virtual Annual Meeting, May 15-19, 2020.

168. Song H, Duan H, Harrison C, Guja K, Hatami N, Franc B, Moradi F, Mari Aparici C, Davidzon G, Srinivas S, Iagaru A. Prospective evaluation of 18F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer: analysis of lesion localization and distribution. ASCO Virtual Annual Meeting, May 29-31, 2020.

169. Leonard Z, Ramos K, Nguyen V, Castaneda P, Iagaru A. SUV measurements from images reconstructed with the block sequential regularized expectation maximization algorithm: comparison of motion corrected vs. non-motion corrected data. SNMMI Virtual Annual Meeting, Jul 11-14, 2020.

170. Baratto L, Duan H, Hatami N, Mari Aparici C, Davidzon G, Iagaru A. 68Ga-RM2 PET/CT in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer. SNMMI Virtual Annual Meeting, Jul 11-14, 2020.

171. Moradi F, Baratto L, Duan H, Hatami N, Davidzon G, Sonn G, Iagaru A. 68Ga-PSMA-11 PET/MR Imaging before prostatectomy: correlation with surgical pathology and two-year follow up. SNMMI Virtual Annual Meeting, Jul 11-14, 2020.

172. Duan H, Hatami N, Baratto L, Davidzon G, Mari Aparici C, Gambhir SS, Koglin N, Witteles R, Iagaru A. A pilot study of 18F-FSPG SiPM-based PET/CT in patients referred for exclusion of active cardiac sarcoidosis and negative or non-diagnostic 18F-FDG PET/CT. SNMMI Virtual Annual Meeting, Jul 11-14, 2020.

173. Baratto L, Song H, Duan H, Davidzon G, Moradi F, Iagaru A. Preliminary Results of a Prospective Study of 68Ga-RM2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer and Negative Conventional Imaging. WMIS Virtual Congress, Oct 7-9, 2020.

174. Duan H, Gambhir SS, Koglin N, Witteles R, Iagaru A. A pilot study of 18F-FSPG PET/CT in patients referred for exclusion of active cardiac sarcoidosis and negative, equivocal or non-diagnostic 18F-FDG PET/CT. WMIS Virtual Congress, Oct 7-9, 2020.

175. Baratto L, Song H, Duan H, Davidzon G, Moradi F, Iagaru A. 68Ga-RM2 Gastrin-Releasing Peptide Receptors PET Imaging for Biochemically Recurrent Prostate Cancer in the Era of PSMA: Results of a Prospective Study. EANM Virtual Congress, Oct 23-30, 2020.

176. Song H, Duan H, Harrison C, Guja K, Hatami N, Franc B, Moradi F, Mari Aparici C, Davidzon G, Iagaru A. Prospective Single Institution Study of 18F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer: An Analysis of Lesions Detection and Localization. EANM Virtual Congress, Oct 23-30, 2020.

177. Duan H, Hatami N, Baratto L, Davidzon G, Mari Aparici C, Gambhir SS, Koglin N, Witteles R, Iagaru A. Preliminary Results of 18F-FSPG PET/CT in Patients Referred for Exclusion of Active Cardiac Sarcoidosis after Non-Contributory 18F-FDG PET/CT. EANM Virtual Congress, Oct 23-30, 2020.

178. Nakamoto R, Duan H, Ferri V, Hatami N, Goel M, Kimura R, Wardak M, Haywood T, Shen B, Park W, Iagaru A. Biodistribution and Safety of 18F-FP-R01-MG-F2 Knottin PET Tracer in Patients with Pancreatic Cancer. SNMMI Virtual Annual Meeting, Jul 11-15, 2021.

179. Duan H, Ferri V, Ghanouni P, Daniel B, Hatami N, Davidzon G, Mari Aparici C, Thong A, Sonn GA, Iagaru A. A Pilot Study of 68Ga-PSMA 11 PET/MRI and 68Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer. SNMMI Virtual Annual Meeting, Jul 11-15, 2021.

180. Nakamoto R, Ferri V, Duan H, Hatami N, Goel M, Rosenberg J, Kimura R, Wardak M, Haywood T, Kellow R, Shen B, Park W, Iagaru A, Gambhir SS. Pilot phase study of 18F-FP-R01-MG-F2 PET in pancreatic cancer patients. EANM Virtual Congress, Oct 20-23, 2021.

181. Song H, Duan H, Harrison C, Guja, K, Hatami N, Nguyen J, Moradi F, Mari Aparici C, Franc B, Davidzon G, Srinivas S, Iagaru A. Prospective Evaluation of 18F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer: analysis of 18F-DCFPyL uptake in possible extra-pelvic oligometastases. RSNA Annual Meeting, Chicago, IL. Nov 28 – Dec 2, 2021.

182. Duan H, Hong S, Davidzon G, Moradi F, Iagaru A. Results of First Interim Analysis of 68Ga-NeoB and 68Ga-PSMA R2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer. SNMMI Annual Meeting, Vancouver, BC. Jun 11-14, 2022.

183. Duan H, Ferri V, Castaneda P, Visser T, Luong C, Davidzon G, Mari Aparici C, Iagaru A. Head-to-head Comparison Of A Conventional Or CZT-based SPECT/CT With A Next Generation Multidetector CZT-based SPECT/CT System. SNMMI Annual Meeting, Vancouver, BC. Jun 11-14, 2022.

184. Duan H, Ferri V, Ghanouni P, Daniel BL, Rosenberg J, Hatami N, Davidzon G, Mari Aparici C, Thong A, Sonn G, Kunder C, Iagaru A. A Pilot Study of 68Ga-PSMA11 and 68Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer. SNMMI Annual Meeting, Vancouver, BC. Jun 11-14, 2022.

185. Song H, Duan H, Harrison C, Guja K, Hatami N, Nguyen J, Franc B, Moradi F, Mari Aparici C, Davidzon G, Srinivas S, Iagaru A. Biochemical recurrence after 18F-DCFPyL PET guided therapy of prostate cancer oligometastases. SNMMI Annual Meeting, Vancouver, BC. Jun 11-14, 2022.

186. Ferri V, Zananiri R, Iagaru A. Performance evaluation of a novel multi-detector CZT-based SPECT/CT system using Tc99m and Lu177. SNMMI Annual Meeting, Vancouver, BC. Jun 11-14, 2022.

187. Duan H, Davudzon GA, Moradi F, Liang T, Iagaru A. Modified PROMISE Criteria for Standardized Interpretation of GRPR-targeted PET. EANM Annual Congress, Barcelona, Spain. Oct 15-19, 2022.

188. Duan H, Ferri V, Castaneda P, Visser T, Luong K, Davidzon GA, Mari Aparici C, Iagaru A. Head-to-head Comparison of a Conventional or CZT-based SPECT/CT with a Next Generation Multidetector CZT-based SPECT/CT System. EANM Annual Congress, Barcelona, Spain. Oct 15-19, 2022.

189. Ferri V, Luong K, Castaneda P, Iagaru A. Novel CZT-based multi detector SPECT/CT system: daily QCs and performance evaluation at one year after installation. EANM Annual Congress, Barcelona, Spain. Oct 15-19, 2022.

190. Duan H, Ghanouni P, Daniel B, Rosenberg J, Thong A, Sonn GA, Kunder C, Davidzon GA, Mari Aparici C, Moradi F, Iagaru A. A Pilot Study of 68Ga-PSMA11 and 68Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer. EANM Annual Congress, Barcelona, Spain. Oct 15-19, 2022.

191. Duan H, Ghanouni P, Daniel B, Rosenberg J, Davidzon GA, Mari Aparici C, Thong A, Sonn GA, Kunder C, Iagaru A. Pilot Study of 68Ga-PSMA11 and 68Ga-RM2 PET/MRI for Evaluation of Prostate Cancer Response to High Intensity Focused Ultrasound (HIFU) Therapy. EANM Annual Congress, Barcelona, Spain. Oct 15-19, 2022.

192. Duan H, Davidzon GA, Moradi F, Liang T, **Iagaru A**. Modified PROMISE Criteria for Standardized Interpretation of GRPR-targeted PET. RSNA Annual Meeting, Chicago, IL. Nov 26-30, 2022.

193. Duan H, Davidzon G, Moradi F, Liang T, **Iagaru A**. Modified PROMISE Criteria for Standardized Interpretation of Gastrin Releasing Peptide Receptor (GRPR)-targeted PET. SNMMI Annual Meeting, Chicago, IL. Jun 24-27, 2023.

194. Na SJ, Duan H, Song H, **Iagaru A**. Assessment of the response of treatment with $^{18}$F-DCFPYL PET/CT in patients with prostate cancer. SNMMI Annual Meeting, Chicago, IL. Jun 24-27, 2023.

195. Duan H, Moradi F, Davidzon G, Liang T, **Iagaru A**. Final Analysis of a Prospective, Single-center, Phase II/III Imaging Trial of $^{68}$Ga-RM2 PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer. SNMMI Annual Meeting, Chicago, IL. Jun 24-27, 2023.

196. Zhou W, Moradi F, Davidzon G, Song H, Grady E, Nguyen J, Franc B, Aparici CM, **Iagaru A**, Shah J. A Case-Based Primer on FDG PET/CT for Imaging Cardiovascular Infections: Protocol, Interpretation, and Pitfalls. SNMMI Annual Meeting, Chicago, IL. Jun 24-27, 2023.

197. Song H, Duan H, Ferri V, Na SJ, Davidzon G, Franc B, Aparici CM, Moradi F, **Iagaru A**. Total and Anatomically Contextualized Quantitative 18F-DCFPyL PET at biochemical recurrence predicts subsequent biochemical progression free survival in prostate cancer patients. SNMMI Annual Meeting, Chicago, IL. Jun 24-27, 2023.

198. Moradi F, Khalighi MM, Su KH, Zhang X, Wollenweber S, Spangler-Bickell M, Bharathi PG, Franc B, Davidzon G, **Iagaru A**. Rapid dynamic reconstruction using list mode data for monitoring PET image quality accurately predicts final image noise and perceived quality. SNMMI Annual Meeting, Chicago, IL. Jun 24-27, 2023.

199. Duan H, Moradi F, Davidzon GA, Liang T, Song H, Loening A, Vasanawala S, Srinivas S, Brooks JD, Hancock SL, **Iagaru A**. Final Analysis of a Prospective, Single-center, Phase II/III Imaging Trial of68Ga-RM2 PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer. EANM Annual Congress, Vienna, Austria. Sep 9-13, 2023.

200. Duan H, Davidzon GA, Moradi F, Liang T, Song H, **Iagaru A**. Modified PROMISE Criteria for Standardized Interpretation of Gastrin Releasing Peptide Receptor (GRPR)-targeted PET. EANM Annual Congress, Vienna, Austria. Sep 9-13, 2023.

201. Duan H, Moradi F, Davidzon GA, Liang T, Song H, Loening A, Vasanawala S, Srinivas S, Brooks JD, Hancock SL, **Iagaru A**. RSNA Annual Meeting, Chicago, IL. Nov 26-30, 2023.

## G. Research

### 1. Active

**Title:** A Phase I/IIa open-label, multi-center study to evaluate the safety, tolerability, whole-body distribution, radiation dosimetry and anti-tumor activity of [177Lu]-NeoB administered in patients with advanced solid tumors known to overexpress gastrin-releasing peptide receptor (GRPR)
**Major Goals:** Evaluate the clinical utility of [177Lu]-NeoB administered in patients with advanced solid tumors known to overexpress gastrin-releasing peptide receptor (GRPR).
**Name of PD/PI:** Andrei Iagaru
**Source of Support:** Advanced Accelerator Applications SA
**Project/Proposal Start and End Date**: (MM/YYYY) (if available): 09/01/2019-08/31/2026
**Total Award Amount** (including Indirect Costs): $1,677,170

**Title:** PSMAddition: An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
**Major Goals:** To evaluate 177Lu-PSMA-617 at an earlier stage of prostate cancer than the current FDA approved indication.
**Name of PD/PI:** Andrei Iagaru
**Source of Support:** Novartis Pharmaceuticals Corp
**Project/Proposal Start and End Date:** (MM/YYYY) (if available): 03/10/2022-11/21/2026
**Total Award Amount** (including Indirect Costs): 2,655,396

**Title:** A Phase1a/b Multicenter, Open-Label Trial to Evaluate Safety, Tolerability, and Dosimetry of LY4257496, a GRPR-targeted radioligand therapy, in adults with GRPR-Positive Advanced Solid Tumors
**Major Goals:** To evaluate LY4257496 in various solid malignancies.
**Name of PD/PI:** Andrei Iagaru
**Source of Support:** Eli Lilly And Company
**Project/Proposal Start and End Date:** (MM/YYYY) (if available): 09/02/2025-08/31/2030
**Total Award Amount** (including Indirect Costs): 2,837,617

**Title:** A First-in-human, Phase 1 Dose Escalation and Expansion Study evaluating the Safety, Tolerability and Anti-tumor Activity of 225Ac-FL-020, an anti-PSMA Radioconjugate (RDC), in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)
**Major Goals:** To evaluate 225Ac-FL-020 in patients with advanced prostate cancer.
**Name of PD/PI:** Andrei Iagaru
**Source of Support:** Full Life Technologies
**Project/Proposal Start and End Date:** (MM/YYYY) (if available): 11/25/2024-11/30/2029

**Total Award Amount** (including Indirect Costs): 1,571,545

**Title:** A Phase 1, First-in-human, Multicentre, Open-label,Dose-escalation Study of 225 Ac-FPI-2068 in Adult Patients with Advanced Solid Tumours
**Major Goals:** To evaluate 225 Ac-FPI-2068 in various solid malignancies.
**Name of PD/PI:** Andrei Iagaru
**Source of Support:** Astra Zeneca
**Project/Proposal Start and End Date:** (MM/YYYY) (if available): 01/27/2025-12/31/2029
**Total Award Amount** (including Indirect Costs): 1,368,301

**Title:** Novel MUC1 Theragnostic Peptides for Imaging and Treatment of Triple-Negative Breast Cancer
**Major Goals:** Development novel theragnostic peptides targeting mucin1 that can be used for diagnostic imaging and targeted radionuclide therapy of triple-negative breast cancer
**Name of PD/PI:** Corinne Beinat
**Source of Support:** National Institutes of Health
**Project/Proposal Start and End Date:** (MM/YYYY) (if available): 03/01/2024-2/28/2029
**Total Award Amount** (including Indirect Costs): $2,965,797

**Title:** Novel applications and translation of [18F]hGTS13, a system xc- specific radiopharmaceutical
**Major Goals:** To investigate the application of [18F]hGTS13 in the context of ferroptosis and clinical translation for first-in-human investigation
**Name of PD/PI:** Corinne Beinat
**Source of Support:** National Institutes of Health
**Project/Proposal Start and End Date:** (MM/YYYY) (if available): 07/2024-06/2029
**Total Award Amount** (including Indirect Costs): $ 2,698,162

**Title:** Development of a high-throughput discovery pipeline and low-cost distribution network for personalized molecular imaging and therapy
**Major Goals:** To enable de novo target selection and protein design for imaging and therapy in pancreatic, ovarian and head and neck cancers in both preclinical and proof-of-concept human studies
**Name of PD/PI:** Katherine Ferrera
**Source of Support:** Advanced Research Projects Agency for Health
**Project/Proposal Start and End Date:** (MM/YYYY) (if available): 1/01/2024 – 12/31/2028
**Total Award Amount** (including Indirect Costs): $43,282,192

**Title:** Development of a theragnostic radiopharmaceutical for pancreatic cancer
**Major Goals:** To develop novel radiolabeled peptides for imaging and radionuclide therapy of pancreatic cancer
**Name of PD/PI:** Katherine Ferrara
**Source of Support:** National Institutes of Health
**Project/Proposal Start and End Date:** (MM/YYYY) (if available): 04/01/2024-03/31/2029
**Total Award Amount** (including Indirect Costs): $3,796,172

**2. Pending**

**Title:** A Dose Escalation and Dose Optimization Phase 1a/1b Study to Evaluate Safety, Tolerability and Dosimetry of Radioligand Therapy with LY4337713 in Adults with FAP-Positive Solid Tumors (FiREBOLT)
**Major Goals:** To evaluate LY4337713 in various solid malignancies.
**Name of PD/PI:** Andrei Iagaru
**Source of Support:** Eli Lilly And Company
**Project/Proposal Start and End Date:** (MM/YYYY) (if available): 12/01/2025-11/30/2030
**Total Award Amount** (including Indirect Costs): 960,575

3. **Completed**

| | |
|---|---|
| Source: | ART |
| Title: | Adjunctive Efficacy Study of the SoftScan Optical Breast Imaging System |
| Role: | Co-Investigator |
| Period Covered: | 2006 - 2009 |

Goal: To investigate a novel optical scanner for detection of malignant breast lesions

Source: Genentech
Title: PET Imaging of Lymphoma Patients Using Radiolabeled Rituximab
Role: Co-Investigator
Period Covered: 2007 - 2009
Goal: To develop a novel radiopharmaceutical for PET imaging of lymphoma patients

Source: Stanford Cancer Institute
Title: $^{18}$F FPPRGD$_2$ PET/CT in Patients with Breast Cancer
Role: Principal Investigator
Period Covered: 2010 - 2011
Goal: To evaluate $^{18}$F FPPRGD$_2$ PET/CT in breast cancer

Source: Ivy Foundation
Title: $^{18}$F FPPRGD$_2$ PET/CT, $^{18}$F FDG PET/CT and MRI Evaluation of Response to Anti-Angiogenesis Therapy in Recurrent Glioblastoma Multiforme
Role: Co-Investigator
Period Covered: 2010 - 2016
Goal: To evaluate a new integrin receptor PET radiopharmaceutical for evaluation of response to anti-angiogenesis therapy in patients with recurrent GBM

Source: NIH (ICMIC P50)
Title: Monitoring Response to Targeted Therapy in Non-Small Cell Lung Cancer using $^{18}$F FPPRGD$_2$ PET/CT and *In-Vitro* Diagnostics
Role: Co-Investigator (PI: Sanjiv Sam Gambhir)
Period Covered: 2010 - 2015
Goal: To evaluate a new integrin receptor PET radiopharmaceutical for evaluation of response to anti-angiogenesis therapy in patients with NSCLC

Source: GE Healthcare
Title: Comparison of Combined $^{18}$F NaF/$^{18}$F FDG PET/CT and WBMRI for Skeletal Metastases Detection
Role: Principal Investigator
Period Covered: 2012 - 2014
Goal: To evaluate PET/CT and WBMRI in detection of skeletal metastases

Source: Stanford Cancer Institute
Title: $^{18}$F FPPRGD$_2$ PET/CT in Patients with Sarcoma
Role: Principal Investigator
Period Covered: 2012 - 2013
Goal: To evaluate $^{18}$F FPPRGD$_2$ PET/CT in angiosarcoma

Source: Department of Radiology, Stanford University
Title: PET Imaging of Lymphoma Patients Using Radiolabeled Rituximab
Role: Principal Investigator
Period Covered: 2012 - 2013
Goal: To test a novel radiopharmaceutical for PET imaging of lymphoma patients

Source: Bayer Healthcare
Title: Alpharadin in Castration-Resistant (Hormone Refractory) Prostate Cancer Patients with Bone Metastases
Role: Principal Investigator
Period Covered: 2012 - 2014
Goal: To test a novel radiopharmaceutical for therapy of bone metastases

Source: Piramal Imaging, GmbH
Title: $^{68}$Ga-RM2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer and Negative Conventional Imaging
Role: Principal Investigator

Period Covered: 2015 - 2016
Goal: To evaluate a new gastrin releasing peptide receptor PET radiopharmaceutical for evaluation of disease extent in patients with recurrent prostate cancer

Source: Bayer Healthcare
Title: Combined "One Stop Shop" NaF/FDG PET/MRI Evaluation of Response to Ra-223 in mCRPC Patients
Role: Principal Investigator
Period Covered: 2015 - 2017
Goal: To test a novel diagnostic approach for evaluation of response to therapy of bone metastases

Source: GE Healthcare
Title: External Validation of the Next Generation PET/CT System
Role: Principal Investigator
Period Covered: 2016 - 2017
Goal: To test a novel PET/CT scanner

Source: GE Healthcare
Title: Combined $^{18}$F NaF/$^{18}$F FDG PET/MRI for Skeletal Metastases Detection
Role: Principal Investigator
Period Covered: 09/2014 - 08/2018
Goal: To evaluate PET and MRI in detection of skeletal metastases

Source: GE Healthcare
Title: PET/MRI of Cardiac Amyloid
Role: Principal Investigator
Period Covered: 09/2016 - 08/2018
Goal: To test a novel radiopharmaceutical for PET imaging of patients with suspected cardiac amyloid

Source: GE Healthcare
Title: PET/MRI of Cardiac Sarcoid
Role: Principal Investigator
Period Covered: 09/2016 - 08/2018
Goal: To test a novel radiopharmaceutical for PET imaging of patients with suspected cardiac sarcoid

Source: GE Healthcare
Title: $^{68}$Ga-PSMA PET/MRI in Patients with Newly Diagnosed Intermediate and High-Risk Prostate Cancer
Role: Principal Investigator
Period Covered: 09/2016 - 08/2018
Goal: To evaluate a new prostate specific membrane antigen PET radiopharmaceutical for evaluation of disease extent in patients with recurrent prostate cancer

Source: GE Healthcare
Title: Advanced Research for Digital PET/CT
Role: Principal Investigator
Period Covered: 09/2016 - 02/2020
Goal: To evaluate the new SiPM-based PET detectors in various clinical applications

Source: National Institutes of Health (Project 117724)
Title: Center for Cancer Nanotechnology Excellence for Translational Diagnostics (CCNE-TD)
Role: Co-Investigator
Period Covered: 09/2015 - 07/2020
Goal: The major goal of this project is to develop in vitro diagnostics and in vivo molecular imaging using novel nanotechnology strategies. Included are cell sorting and cell analysis technologies as well as self-assembling nanoparticles and nano bubbles.

Source: Advanced Accelerator Applications USA, Inc.
Title: A Phase 1/2 open-label, multi-center, dose-escalation study of safety, tolerability, pharmacokinetics, dosimetry, and response to repeat dosing of $^{177}$Lu-PSMA-R2 radio-ligand

therapy in patients with prostate specific membrane antigen (PSMA) positive ($^{68}$Ga-PSMA-R2) progressive metastatic castration-resistant prostate cancer, following previous systemic treatment.
Role: Principal Investigator
Period Covered: 11/2018 - 11/2021
Goal: To evaluate a new radioligand therapy in prostate cancer.

Source: Endocyte, Inc.
Title: An International, prospective, open-label, multicenter, randomized phase 3 study of $^{177}$Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistent prostate cancer (MCRPC) of $^{177}$Lu-PSMA617
Role: Co-Investigator
Period Covered: 12/2018 - 12/2021
Goal: To evaluate a new radioligand therapy in prostate cancer.

Source: Department of Defense
Title: $^{68}$Ga Bombesin PET/MRI in Patients with Biochemically Recurrent Prostate Cancer and Noncontributory Conventional Imaging
Role: Principal Investigator
Period Covered: 10/2016 - 09/2021
Goal: To evaluate a new PET radiopharmaceutical for detection of recurrent prostate cancer.

Source: National Institutes of Health
Title: Next Generation Sentinel Node Mapping
Role: Co-Investigator
Period Covered: 12/2019 - 11/2021
Goal: To evaluate $^{89}$Zr-Panitumumab as a novel PET radiopharmaceutical for sentinel lymph node mapping in head and neck cancers.

Source: GE Healthcare
Title: External Validation of the Next Generation SPECT CT System
Role: Principal Investigator
Period Covered: 09/2021 - 08/2022
Goal: To evaluate the new CZT-based SPECT detectors in various clinical applications.

Source: NIH (5U01CA21002002)
Title: Molecular Imaging Methods for the Detection of Pancreatic Ductal Adenocarcinoma.
Role: Principal Investigator
Period Covered: 05/2017 - 04/2023
Goal: To evaluate new strategies for early detection of prostate cancer.

Source NIH (1R01 CA230438-01A1)
Title: Evaluation of Patients with Low-Risk and Intermediate-Risk Prostate Cancer Scheduled for High-Dose Rate Brachytherapy Using $^{68}$Ga-RM2 PET, $^{68}$Ga-PSMA-11 PET and Multi Parametric MRI
Role: Principal Investigator
Period Covered: 08/2019 - 07/2023
Goal: To evaluate the use of $^{68}$Ga-RM2 PET/MRI and $^{68}$Ga-PSMA-11 PET/MRI to guide high-dose rate brachytherapy, evaluate response and predict progression-free survival in men with intermediate-risk prostate cancer.

Source: General Electric Healthcare
Title: Predictive and real-time PET image quality monitoring using machine learning
Role: Co-Investigator
Period Covered: 04/2022 - 04/2024
Goal: To use machine learning for assessment of PET image quality in real time in order to reduce errors in image acquisitions.